Touro Scholar
NYMC Student Theses and Dissertations

Students

8-31-2020

Preclinical Studies on Intranasal NPY and Selective NPY Receptor
Agonists in Rodent PTSD Model: Focus on Locus Coeruleus
Noradrenergic System
Chiso Nwokafor

Follow this and additional works at: https://touroscholar.touro.edu/nymc_students_theses
Part of the Medical Biochemistry Commons

Preclinical Studies on Intranasal NPY and
Selective NPY Receptor Agonists in Rodent PTSD
Model: Focus on Locus Coeruleus Noradrenergic
System
Chiso Nwokafor
A Doctoral Dissertation in the Program in Biochemistry
and Molecular Biology
Submitted to the Faculty of the Graduate
School of Basic Medical Sciences
in Partial Fulfillment of the Requirements
for the Degree of Doctor of Philosophy
at New York Medical College

2020

Preclinical Studies on Intranasal NPY and Selective NPY Receptor
Agonists in Rodent PTSD Model: Focus on Locus Coeruleus
Noradrenergic System

Chiso Nwokafor

�-������1

pl.O.

Esther L. Sabban, Ph.D.
Sponsor

U�;� m� PLO.
1

Susan OIson, Ph.D.

J'� £;:,
Committee Member

ohn Pinto, Ph.D. 1 /[D.

Committee Member

/n:e,14.., µJt,,-

4,,(._,

Joseph Wu, Ph.D.
Committee Member
Christopher Leonard, Ph.D.
Committee Member

7/11/2020

Date of approval

This dissertation is dedicated to my parents, for their love, support, inspiration and
encouragement through the years.

iii

ACKNOWLEGEMENTS
I would like to thank my mentor, Dr. Esther L. Sabban, for granting me the wonderful
opportunity to train in her laboratory. I am forever grateful for her encouragement, support
and guidance throughout this project.
I would like to thank my committee members, Dr. Susan Olson, Dr. John Pinto, Dr.
Christopher Leonard and Dr. Joseph Wu for their very insightful contributions to this
project and their guidance throughout my thesis work.
I would like to thank Dr. Lidia Serova for her initial guidance with many of the techniques
I utilized in my thesis work and as well as other members of Dr. Sabban’s laboratory,
Roxanna Nahvi and Arax Tanelien for helpful discussions.
I would like to thank the faculty of the Biochemistry Department: Dr. Ernest Lee, Dr.
Arthur Cooper, Dr. Marietta Lee, and Dr. Zhongtao
I would like to thank the Biochemistry Department office staff: Jeanne Chamas, Cindy
Mahamad and Deborah Nicol
I would like to thank Dr. Marina Holz, Dr. Belloni and the Graduate School of Basic
Medical Sciences at New York Medical College for giving me this wonderful learning
opportunity and experience.
I would like to acknowledge the funding for this work from Department of Defense Broad
Agency Announcement for Extramural Medical Research #W81XWH‐16‐1‐0016 and
NYMC/Touro Bridge Funding Program.
Lastly, I would like to thank my wife, Chidinma, children and entire family for their love
and support.

iv

TABLE OF CONTENTS
Title……………………………………………………………………………… i
Signatures...…………………………………………………............................... ii
Dedication……………………………………………………………………….. iii
Acknowledgements.……………………………..………………………………..iv
Table of contents ……...………………………….................................................v
List of figures……………………………………………………………..............vi
List of tables………………………………………………………………………viii
Abbreviations ……………………………………………………………………. ix
Abstract…………………………………………………………………………... xi
Introduction………………………………………………………………………..1
Aims ………………………………………………………………………………. 3
Animal Models of Stress ………………………………………………………….27
Methods…………………………………………………………………………… 32
Results ……………………………………………………………………………..46
Discussion …..…………………………………………………………………... 110
Limitations………………………………………………………………………...130
Future experiments……………………………………………………………….131
References ………………………………………………………………...............133

v

LIST OF FIGURES

Figure 1. HPA axis………………………………………………………………..6
Figure 2. Major afferent and efferent projections of the LC…………………..8
Figure 3. LC/NE Noradrenergic System…………………………………...........12
Figure 4. Norepinephrine Transporter………………………………………….13
Figure 5. Neuropeptide Y(NPY)…………………………………………………16
Figure 6. Therapeutic potential of NPY receptor ligands……………………...19
Figure 7. Neuropeptide Y receptors subtype selectivity…………………..........21
Figure 8. Intranasal Pathway Schematic………………………………………...24
Figure 9. NPY Levels in Brain Regions after Intranasal Infusion………..........26
Figure 10. SPS Schematic………………………………………………………... 31
Figure 11. Anxiety index at one and two weeks after SPS……………………...47
Figure 12. Effect of NPY to reverse symptoms of anxiety……………………....50
Figure 13. Effects of NPY on Risk Assessment and Locomotion……………….53
Figure 14. Reversal of depressive-like symptoms…………………………..........55
Figure 15. Administration of NPY reversed hyperarousal symptoms………….58
Figure 16. Sustained reversal of ASR by NPY…………………………………...60
Figure 17A. Experiment design for agonists (Experiment 1)……………………63
Figure 17B. Experiment design for agonists (Experiment 2)……………………64
Figure 17C. Experiment design for agonists (Experiment 3)……………………65
Figure 17D. Experiment design for agonists (Experiment 4)……………………66
Figure 17E. Experiment design for agonists (Experiment 5)……………………67
Figure 18. Effects of Y1R agonists on anxiety and depressive behavior..............70
Figure 19. Effects of Y1R receptor agonist on anxiety behavior………………..72
Figure 20. Effects of Y2R receptor agonist on anxiety & depression…………...74
Figure 21. Effects of [D-His26] NPY and NPY receptor agonists on anxiety……76
Figure 22. Effects of [D-His26] NPY receptor agonist on ASR…………………...78
Figure 23. Changes in the CRH and NPY system in the LC……………………..81
Figure 24. Changes in the CRH and NPY system in the hypothalamus………...83
vi

Figure 25. Changes in the NET expression in the LC………………………........88
Figure 26. Changes in the NET expression in the LC….…………………………89
Figure 27. Effect of intranasal NPY on NET mRNA levels in the LC…………...91
Figure 28. Mean amplitudes of startle……………………………………………..94
Figure 29. Changes in gene expression in the mediobasal hypothalamus……….96
Figure 30. Changes in gene expression in the locus coeruleus…………………... 98
Figure 31. ASR and NET gene expression in the locus coeruleus……………… 100
Figure 32. NET mRNA expression and ASR correlation…………………............101
Figure 33. NET mRNA expression……………………………………………….. 104
Figure 34. NET promoter methylation analysis…………………………….......... 105
Figure 35. CpG methylation…………………………………………………..........106
Figure 36. NET protein expression………………………………………………...108
Figure 37. Proposed mechanism of Y1R biased ligand G protein signaling…….116
Figure 38. Summary of gene expression in the LC and hypothalamus…………117

vii

LIST OF TABLES

Table 1. Relative distribution of NPY receptors in the CNS………………. 20
Table 2. Concentration of NPY in CSF and plasma 30 min after IN NPY
administration…………………………………………………………………. 25
Table 3. Changes in mRNA expression in the LC…………………............... 85
Table 4. Changes in mRNA expression in mediobasal hypothalamus (1-week post
SPS)……………………………………………………………………............. 85
Table 5. Changes in mRNA expression in mediobasal hypothalamus (2-weeks post
SPS)…………………………………………………………………………… 85
Table 6. Representative qPCR program…………………………………… 86
Table 7. Representative amplification raw data…………………………….. 87
Table 8. Representative melting point raw data…………………………….. 87
Table 9. NPY Receptor Affinity……………………………………………… 113

viii

ABBREVIATIONS

ACTH: Adrenocorticotropic hormone
ADHD: Attention deficit hyperactivity disorder
ASR: Acoustic startle response
BBB: Blood brain barrier
BLA: Basolateral amygdala
CA: Closed arm
CRH: Corticotropin-releasing hormone
CRHR1: Corticotropin-releasing hormone receptor 1
CNS: Central Nervous System
CRF: Corticotropin-releasing factor
CSF: Cerebrospinal fluid
DAT: Dopamine transporter
EPM: Elevated plus maze
FST: Forced swim test
FKBP5: FK506 binding protein 5
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase
GR: Glucocorticoid receptor
HPA: Hypothalamic-pituitary-adrenocortical axis
ICV: Intracerebroventricular injection
KO: Knock out
LC-NE: Locus coeruleus/norepinephrine
LC: Locus coeruleus
MR: Mineralocorticoids
NE: Noerpinephrine
NET: Norepinephrine transporter
NPY: Neuropeptide Y
OA: Open arm
PTSD: posttraumatic stress disorder
ix

PVN: Paraventricular nucleus
SI: Social interaction
SLC6A2: Solute Carrier Family 6 Member 2
SPS: Single Prolonged stress
SSRI: Selective serotonin reuptake inhibitor
TSS: Transcription start site

x

Abstract
Post-traumatic stress disorder (PTSD) is a debilitating psychological disorder that
develops in a subset of individuals after exposure to a traumatic stress. Neuropeptide Y
(NPY) an endogenous 36 amino acid neuropeptide expressed in many areas of the brain
and periphery especially those involved in stress may confer resilience to the harmful
effect of stress.
We demonstrated changes in the Single Prolonged Stress (SPS) PTSD model and
potential for their modulation by delivery of intranasal NPY to the brain. There was a
progressive worsening of anxiety symptoms at two weeks compared to one week after
SPS. Previously we showed that 150µg of NPY was effective to reverse anxiety,
depressive-like and hyperarousal symptoms one week after SPS, however this dose was
not sufficient to reverse anxiety symptoms two weeks after SPS when symptoms have
become more severe. We determined that doubling NPY dose to 300µg was sufficient to
reverse symptoms of anxiety, depression and hyperarousal two weeks after more severe
symptoms have manifested.
Activation of the NPY Y1R subtype was sufficient to prevent the development of
SPS elicited anxiety, social impairment and depressive-like behavior. Moreover, intranasal
delivery of [D-His26] NPY was superior to NPY for preventing depressive-like behavior
and has promise as an early intervention therapy following traumatic stress. Significant
molecular impairments in gene expression for corticotrophin releasing hormone (CRH)
and neuropeptide Y (NPY) systems in the locus coeruleus (LC) and mediobasal
hypothalamus were observed two weeks following SPS. There was a divergence in the
expression levels of the norepinephrine transporter (NET) mRNA in the LC after SPS,
some animals had significantly higher NET mRNA levels and some had levels were
xi

similar or lower than unstressed controls. Nevertheless, NET protein levels were reduced
in the hippocampus; projection region, likely by increasing noradrenergic activation. The
SPS triggered hyperarousal was associated with the changes in NET gene expression.
Animals with increased startle response also had increased NET mRNA. Within the
subgroup of animals that had a lower acoustic startle response, there was a significant
negative correlation with NET mRNA expression. Furthermore, SPS showed a potential
effect in the epigenetic regulation of the NET. Increased methylation of the NET gene
promoter region was observed in the lower NET responsive group and was associated with
a reduction in NET mRNA expression.
Overall these results shed new insights into mechanisms for resilience or
susceptibility to development of hyperarousal, a diagnostic feature of PTSD and that NPY
or a specific Y1R agonist (D-His26)NPY can effectively treat core symptoms of PTSD in
an animal model.

xii

Introduction
Post-Traumatic Stress Disorder (PTSD)
Post-traumatic stress disorder (PTSD) is a debilitating neuropsychiatric disorder that
affects a subset of individuals exposed to severe or life-threatening traumatic stress. PTSD
is characterized (DSM-5) by persistent symptoms for at least a month after the trauma:
which include: intrusive memories such as flashbacks or nightmares; avoidance of stimuli
associated with the trauma; hyperarousal or hypervigilance state; negative alterations of
cognition and mood associated with the traumatic event.
Burdens associated with PTSD and its comorbidities are extremely severe. PTSD is
comorbid with anxiety disorders, substance abuse, sleep disturbances and worsening
medical conditions

1-3

. Individuals with PTSD have a high risk for suicide and indeed

PTSD related suicide is the 10th leading cause of death in the United States 4. The
symptoms of PTSD can be very long lasting, with enormous personal and society cost.
Some symptoms, such as cognitive abnormalities actually worsen with time 5. The
disorder can persist for more than 40 years 6. Therefore, it is extremely important to
understand the mechanisms of resilience or susceptibility to development of PTSD and to
be able to increase resilience. Early childhood adversary, by way of epigenetic changes, is
associated with increased susceptibility 7.
Treating PTSD can help to regain a sense of control over one’s life. Treatments
include psychotherapy and/or medications. Combining these treatments can help improve
PTSD symptomology; however, the use of medications has not been very effective. For
example, paroxetine and other selective serotonin reuptake inhibitors (SSRIs) are FDA
approved medications for PTSD treatment but have not been sufficiently effective in

treating PTSD

8, 9

consequently resulting in a dire need for effective and more specific

PTSD treatments.

2

AIMS
Aim 1A: Evaluate progression in the development of anxiety symptoms and gene
expression changes in the mediobasal hypothalamus and the locus coeruleus (LC) in the
single prolonged stress (SPS) animal model of PTSD.
Aim 1B: Assess whether Neuropeptide Y (NPY) can effectively reverse PTSD core
symptoms in the PTSD animal model.
Aim 2: Determine the NPY receptor subtype that is sufficient to prevent development of
anxiety and depressive like effects.
Aim 3: Evaluate gene expression changes in the LC and mediobasal hypothalamus and the
role of norepinephrine transporter (NET) in hyperarousal symptoms

3

Engagement of the hypothalamic pituitary adrenal (HPA) axis and the LC/NE in
post-Traumatic Stress Disorder (PTSD)
Post-traumatic stress disorder (PTSD) leads to the dysregulation of the
hypothalamic pituitary adrenal (HPA) axis (Figure 1). Considerable clinical evidence also
suggests the impairment in the locus coeruleus/norepinephrine-autonomic (LC/NE)
noradrenergic system. 10-12. The HPA neuroendocrine axis and the LC/NE nervous system
are important parts of highly conserved stress regulatory systems and are involved in the
development and manifestation of PTSD 13, 14.
The HPA axis consists of direct and feedback interactions among the
hypothalamus, the pituitary gland and the adrenal gland (Figure 1) comprising the
neuroendocrine system controlling reactions to stress and regulates

15

many body

processes. Activation of the HPA axis depends on type of stressor and duration. Stress
drives the HPA stress response, and feedback mechanisms effectively terminate the
response after the stressor becomes less intense or subsides. Corticotrophin releasing
hormone (CRH), a principle regulator of the HPA axis is synthesized and secreted by
neurons localized in the medial parvocellular subdivision of the paraventricular nucleus
(PVN)

16, 17

. CRH is secreted from the PVN of the hypothalamus in response to stress.

CRH stimulates the pituitary gland to secrete adrenocorticotropic hormone (ACTH)
(Figure 1). The pituitary gland releases ACTH into the bloodstream. ACTH in the blood
stream binds to receptors on the surface of the adrenal cortices eliciting intracellular events
that result in the adrenal glands secreting glucocorticoids. Under normal physiological
conditions, glucocorticoids increase glucose supply to skeletal muscles, providing the
body with extra energy to respond to stressors. The normal functioning of the HPA axis
is essential for coping with stress, but repeated or chronic stress has the potential to disrupt
the beneficial physiological role of the HPA axis.
4

Glucocorticoids bind to mineral corticoid (MR) with higher affinity than they do to
the glucocorticoid receptor (GR)

18, 19

. Both GR and MR operate in a complementary

fashion to regulate HPA-axis. GR is expressed ubiquitously in the brain while MR is
predominately expressed in limbic areas such as the hippocampus and amygdala 20-22. Due
to a higher affinity of glucocorticoids to MR, the MR has a higher occupancy rate in nonstressful conditions in order to maintain low basal corticosteroid levels through negative
feedback 21. However, full GR occupancy is only reached at peak cortisol concentrations
such as during stress. Impairments in GR and HPA regulators such as FK506 binding
protein 5 (FKBP5) have been associated with PTSD susceptibility 23.
GR plays an essential role in glucocorticoid feedback when it is activated by ligand,
it represses CRH biosynthesis via a direct negative feedback on the hypothalamus which
leads to the termination of the stress response. FKBP5 can modulate GR sensitivity to its
ligand and FKBP5 mRNA and protein expression are induced by GR activation via
intronic hormone response elements providing an ultra-short feedback loop for regulating
GR-sensitivity 24.
Polymorphisms in the FKBP5 gene have been associated with differences in GR
sensitivity, stress hormone system regulation and biologically distinct subtypes of PTSD
and can predict the severity of its onset 25, 26.

5

Figure 1 - HPA axis

Adapted from Menke et al., Front. Psychiatry, 28 February 2019 27.
Figure 1.

Hypothalamic Pituitary Adrenal (HPA) axis regulation. Corticotrophin-

releasing hormone (CRH) is released by neurons in the paraventricular nucleus of the
hypothalamus (1). Subsequently CRH receptors are activated and the secretion of
adrenocorticotropic hormone (ACTH) from the pituitary is induced (2). ACTH induces the
release of glucocorticoids (cortisol) by the adrenal glands. After the activation of the HPA
axis, negative feedback loops are activated to reinstate homeostasis by cortisol activating
glucocorticoid receptors (GR). The unliganded GR complex consists of the co-chaperones
FKBP51 or FKBP52 (encoded by their respective genes FKBP5 and FKBP4), p23 (a cochaperone molecule) and hsp90 dimer. When FKBP51 binds to the GR-complex via
hsp90, the GR affinity for cortisol is reduced. When glucocorticoids bind to the GR,
FKBP51 is exchanged against FKBP52 and the nuclear translocation of the ligand-bound
GR is enabled. The GR directly binds to the DNA via glucocorticoid response elements
6

(GREs) and induces FKBP5 mRNA expression (3) and subsequently FKBP51 production,
inducing an ultra-short negative feedback loop on GR sensitivity.
Locus coeruleus/norepinephrine-autonomic (LC/NE) noradrenergic system.

The LC is situated deep in the pons and sends projections to most brain regions,
including the brainstem, the cerebellum, the diencephalon and the paleo- and neocortex
CNS. It is comprised of neurons in rats and the main source of norepinephrine (NE) in the
brain

28

. The actions of NE are very diverse suggesting that the LC is engaged in many

functions. The LC-NE is one of the first systems to be engaged following a stressful event.
LC neurons display increased activity in response to arousing stimuli but during quiet
wakefulness neurons in the LC are less active and their activity diminishes during rapid
eye movement, or REM, sleep. Physiological levels of norepinephrine in the prefrontal
cortex, an area of the brain involved with attention, has been shown to be important in the
facilitation of attention-related tasks. The LC/NE system is integral to a number of higher
cognitive functions ranging from, fine-tuning sensory signals, to motivation and working
memory.

7

Figure 2 - Major afferent and efferent projections of the LC

Figure 2. Afferent (red and purple) and efferent projections of LC neurons (blue). LC,
locus coeruleus; NA, noradrenaline; Alpha2, Alpha2 receptor; GABA, γ-aminobutyric
acid; GABA A, GABA A receptor; 5-HT, serotonin; 5-HT1 and 5-HT2, serotonin receptor
subtype 1 and 2; CRF, corticotropin releasing factor; STN, subthalamic nucleus; VTA,
ventral tegmental area; SN, substantia nigra; NET, noradrenalinergic transporters; Red,
excitatory input; Purple, inhibitory input.
Adapted from Delaville et al., Frontiers in Systems Neuroscience, 201129.

8

Stress increases activity and subsequently gene expression of NE‐producing
enzymes, tyrosine hydroxylase (TH) and dopamine β‐hydroxylase (DBH) 30-32. Increased
tonic activity of the LC-NE system is necessary and sufficient for stress-induced anxiety
and aversion 33. Endogenous corticotropin releasing hormone (CRH) from the amygdala
induces anxiety-like behaviors via its terminals in the LC and increases the tonic firing
activity of LC neurons 33. Optogenetics a method for controlling a neuron’s activity using
light and genetic engineering was used for stimulation of the LC. Norepinephrine release
in the basolateral amygdala (BLA) increased anxiety-like behavior following
photostimulation of LC-NE fibers

33

. The increased NE release in the BLA mediate an

anxiety-like phenotype via β-adrenergic receptors 33. Chronic and repeated stress leads to
increased changes in signaling pathways and more sustained transcriptionally mediated
induction of TH and DBH, yielding elevated NE levels in some terminal fields 31, 32, 34-36.

Elevated levels of NE in the CSF has been directly linked to severity of PTSD core
symptoms in patients 37 and increased LC activity has been linked to hyperarousal and reexperiencing features of PTSD
formation of specific memories.

38

. The LC-hippocampal network is involved in the
LC neurons originally defined by their canonical

norepinephrine noradrenaline NE) signaling, mediate post encoding novelty-associated
enhancement of memory retention in a manner consistent with possible co-release of DA
along with NE in the hippocampus 39. A memory is formed immediately upon experience
and can last up to a lifetime. Input from LC to CA3 is essential for the formation of a
persistent memory in the hippocampus

40

. Elevating noradrenergic activity at alpha-1-

receptors (α-1-ARs) in the medial prefrontal cortex also facilitates cognitive performance
of rats in an attentional set-shifting task,
flexibility in rats

41

a measure of attention and cognitive

. However, overstimulation of medial prefrontal cortex (mPFC)

projecting LC cells disrupted the memory extinction process through activation of α-19

ARs in mPFC 42. Several groups have demonstrated that LC-NE neurons are activated by
many different stressors. Selective inhibition of LC-NE neurons during stress prevents
subsequent anxiety-like behavior. Exogenously increasing tonic activity of LC-NE
neurons is alone sufficient for anxiety-like and aversive behavior

33

. McCall et al. also

found that endogenous corticotropin-releasing hormone(+) (CRH(+)) LC inputs from the
amygdala increase tonic LC activity, inducing anxiety-like behaviors

33

. Based on these

studies the LC-NE system is a critical mediator of stress-induced anxiety and critical target
for therapeutic intervention to prevent stress-related affective disorders.

Norepinephrine transporter (NET)
The LC-NE signaling is controlled to a large extent by norepinephrine transporters
(NET) by mediating the rapid clearance of NE from the synaptic cleft and maintaining NE
storage in the pre-synaptic noradrenergic cells (Figure 4) 43, 44. NET belongs to the family
of sodium chloride neurotransmitter transporters 45, 46 with its concentration highest in the
LC and can be found in lower concentrations in the cortical and subcortical regions,
including the frontal cortex, hippocampus, amygdala, thalamus, and cerebellar cortex

47

.

NET knockout mice have a lower rate of extracellular NE clearance in the brain and
elevated extracellular NE concentrations in plasma as well as altered dopamine signaling
48, 49

. They also display higher resistance to convulsions 50. NET are targets for the action

of many drugs used to treat major depression 51. Stimulant drugs that act on both NET and
DA transporters (DAT) are used to treat attention deficit/hyperactivity disorder (ADHD),
however a NET selective drug (reboxetine) has been shown to have good efficacy in
treating ADHD 52. In addition, the engagement of NE systems in response to stress suggest
that NE is implicated in disorders triggered by trauma events such as in post-traumatic
stress disorder and depression

53

and

noradrenergic activation has been shown to

10

significantly affect the maintenance of arousal, an important cognitive function impaired
in ADHD.
Furthermore, psychiatric and cardiovascular phenotypes have resulted from
nonsynonymous single nucleotide polymorphisms (SNPs) leading to amino acid
substitutions in hNET

54-57

. NET availability in the locus coeruleus and limbic brain

regions of PTSD patients was decreased compared to healthy controls

58

. Characterizing

NET availability following the healthy human adaptation of stress and the development of
PTSD would shed light on noradrenergic contributions to the human stress response. More
recently DNA methylation has received increased attention as a possible modulator in
psychiatric disorders in addition to the influence of genetic polymorphisms.
DNA methylation is a biological process by which methyl groups are added to
the DNA molecule at CpG sites, which can change the activity of a DNA segment without
changing the sequence. If methylation occurs at the gene promoter, the gene
transcription.is typically repressed. CpG sites are regions of DNA where a cytosine
nucleotide is followed by a guanine nucleotide in the linear sequence of bases along its 5'
→ 3' direction. A study in veterans showed that low methylation level in a specific NET
promoter region may independently have higher risk of PTSD (Jingmei Zhang, OAT
2016). Another study showed that NET promoter hypermethylation was detected toward
the 5′ end of the promoter in ADHD patients compared to healthy controls. There was a
negative association between hyperactivity–impulsivity symptom scores with NET
methylation levels for several CpG sites 59. In addition, there was a negative correlation
between methylation of a single CpG site with in vivo NET expression in several brain
regions in ADHD patients

59

. The differential methylation seen in these patients may be

due to transcription factors behaving in a distinct manner in ADHD. These studies reveal
the potential effects of epigenetics on behavioral control in health and disease states.
11

Figure 3 – LC/NE Noradrenergic System

Adapted from Feinstein et al., Journal of Neurochemistry, 2016 60.
Figure 3. Locus coeruleus neurons sends projections to virtually every region of the CNS
(blue arrows). In addition, it is the only source of NA to areas of the forebrain and
cerebellum. Maintenance of noradrenergic innervation at some regions, most notably the
forebrain and spinal cord, depends largely upon target‐derived neurotrophin signaling (red
arrows).
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Figure 4 - Release and reuptake of norepinephrine (NE)

Adapted from Zhou et al., Drugs Future 61.
Figure 4. Diagram of a noradrenergic axonal terminal showing the release and reuptake of
norepinephrine (NE). a. NE is synthesized from tyrosine via hydroxylation to form
dihydroxyphenylalanine (Dopa), decarboxylation to form dopamine, and hydroxylation to
form NE, and b stored in vesicles. c. As a result of an appropriate stimulus (not shown),
NE is released into the synaptic cleft. d. Released NE activates the adrenergic receptors
located on the postsynaptic membrane (α1, β1 and β) and the e. presynaptic membrane (α2
and β2) and causes f. postsynaptic reactions such as protein kinase activation and protein
phosphorylation. g. The NET is responsible for reuptake of NE in the synaptic cleft and
terminates its action. h. After reuptake by the NET, a small portion of the NE is restored
in vesicles (following uptake by the vesicular amine transporter 2, VMAT2); I. the rest is
metabolized in the mitochondria by the enzyme monoamine oxidase (MAO), and j. the
product dihydroxyphenylglycol (DHPG) is released into the circulation. k. A small portion

13

of the synaptic NE leaks into the circulation, or l. is taken up by another system (uptake 2)
and m. metabolized to form normetanephrine (NMN).
Neuropeptide Y (NPY)
NPY is a 36 amino acid C-terminal amidated neuropeptide (see Fig 5)
expressed abundantly in the central and peripheral nervous system 62-64. In the brain, it is
synthesized primarily by cell bodies in the arcuate nucleus of the hypothalamus and
transported to the PVN where the highest concentrations are found. NPY is highly
conserved among species and involved in the regulation of many systems throughout the
body such as sleep, appetite, memory, anxiety, fear, and stress 65-67. NPY is also
expressed in sympathetic nerves and the adrenal medulla. In sympathetic excitation
NPY is co-expressed with NE and enhances the vasoconstrictor effect of NE as well as
that of angiotensin II 68, 69. NPY immunoreactive fibers are present in high density in the
mammalian heart and vicinity of blood vessels and play a role in the excitationcontraction (EC) coupling in cardiomyocytes and vascular smooth muscle cells.
It is synthesized in GABAergic neurons and expressed mainly in interneurons 63.
High levels of NPY are found in the hypothalamus, the periaqueductal gray, the septum,
and the locus coeruleus (LC) and the nucleus accumbens

70, 71

. Moderate levels of NPY

are found in the cerebral cortex, amygdala, the basal ganglia, hippocampus and the
thalamus

62, 71

. In the NPY KO animals, mice with both mutant alleles for NPY do not

make detectable NPY messenger RNA in brain or show NPY immunoreactivity in the
brain or adrenal gland. However, a subset of young adult NPY KO mice had mild seizures,
suggesting an inhibitory role of NPY on neural excitability during development

72

.

Increased anxiety-like behavior 73 has been observed in NPY deficient mice. Transgenic

14

overexpression or intracerebroventricular (icv) administration of NPY has been shown to
be anxiolytic and anti-depressive in rats and mice 74-77.
These studies suggest that Neuropeptide Y (NPY) expression is linked with the
development of stress resilience in rodents.
Furthermore, the Sabban laboratory has shown that delivery of NPY to the CNS
in rats by intranasal infusion is effective in preventing development of core PTSD
symptoms, such as anxiety, hyperarousal and depressive-like behavior

78-82

. Intranasal

delivery of NPY after manifestation of some of the PTSD core symptoms reversed the
PTSD-associated symptoms. In both preclinical and clinical models, NPY levels are
associated with resilience to harmful effects of stress 80, 83-90. Patients with depression and
anxiety disorders have abnormally low levels of NPY in plasma and cerebrospinal fluid
(CSF) 85, 91-94. PTSD patients showed a dose-dependent anxiolytic effect of intranasal NPY
in a clinical trial 95.
Overall, pre-clinical and clinical studies show positive correlation of NPY with
resilience to stress thus making NPY a potential therapy for some PTSD symptoms 78, 86,
95-97

.

15

Figure 5 - Structure of Neuropeptide Y (NPY)

Figure 5. NPY is a 36 amino-acid neuropeptide with COOH-terminally alpha-amidated
amino acid.
Adapted from Orbetzova et al., Appetite Regulatory Peptides, 2012 98.

16

NPY receptors
NPY exerts its effects by binding G-protein coupled receptor proteins, Y1R, Y2R,
Y4R and Y5R receptor subtypes with high affinity while Peptide YY, a short peptide
released from cells in the ileum and colon in response to feeding, is the preferred agonist
for the Y4R 65. Y6R has also been cloned however, it is active only in rabbits and mice 99.
NPY receptors are coupled via Gi/o to several downstream pathways including inhibition
of adenylyl cyclase, regulation of intracellular Ca2+, activation of MAPK, inward
rectifying potassium channels, hyperpolarization-activated cation currents (lh) channel
100

89,

.
N- and C-terminal of NPY are essential for NPY binding and activity of Y1R.

Analogues with N-terminal truncations become less specific for the Y1R. The truncation
of the first amino acid NPY(2–36) results in a loss of affinity 101. The C-terminal contains
an amide group and truncations show the importance of the amide group in the binding
with the receptor 102. Positions 7, 25, 26, 31, and 34 are important for subtype selectivity
(Figure 7). [D-Arg25]NPY and [D-His26]NPY bind selectively to the Y1 receptor when
substitutions at positions 25 and 26 are made (Figure 7)

103

. The affinity of the peptide to

Y1/Y5 receptors was achieved with Pro in position 34. Introducing an aromatic amino acid
e.g., Phenylalanine (Phe) at position 7 gives rise to a selective Y1 receptor binder [Phe7,
Pro34]pNPY. In addition combining Pro34 with an exchange in position 31 by Leu
contributes to aY1/Y4/Y5 receptor selectivity 104-106.
The Y1R was the first NPY receptor cloned 107-110 and is well conserved throughout
evolution in mammalian and non-mammalian species. Both the N- and C– terminus are
necessary for NPY to bind to Y1R 101, 102, 111.
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Many of the anti-stress effects of NPY were proposed to be mediated by post
synaptic Y1R or require Y1R, as shown by pharmacological and genetic approaches in
naïve (not previously stressed) animals. For example, [Leu31Pro34]PYY, a Y1R/Y5R
agonist, reduced immobility in Forced Swim Test (FST), while a Y2R agonist was
ineffective 112, 113. The anxiolytic effects of NPY generally is proposed to involve the Y1
receptor subtype 85, 114-118 although Y2 and Y5 receptors have also been implicated 85, 115,
116

. The icv injection of specific Y1 receptor agonist [D-His26]NPY reduced basal anxiety

1 h later 119.
Emerging evidence also suggests an important role for Y2R. NPY knockout (KO)
in mice have increased anxiety and dramatically enhanced acquisition of conditioned fear.
Y1R and Y2R receptor single KO mice exhibited moderate changes in fear processing
while the phenotype of NPY KO mice was fully recapitulated when both Y1R and Y2R
were deleted

120

. Both Y1R agonists and Y2R antagonists induce antidepressant-like

effects in mice 121. Thus, it was proposed that Y2R has a synergistic role with Y1R in fear
acquisition and extinction

122

. Other NPY receptor studies also show that Y4R

preferentially binds pancreatic polypeptide (PP) compared to PYY and NPY. Y4R protein
is expressed in few brain regions including the medial pre-optic area, the paraventricular
hypothalamic nucleus, interpeduncular nuclei and the area postrema

123-125

.

The NPY Y5 receptor has been cloned from human, rat 126, 127 mouse and dog. NPY
Y5 receptor immunoreactivity, binding sites and NPY Y5 receptor mRNA has been
reported in several brain structures, including the limbic system and the brainstem. NPY
Y5 receptor agonist have anxiolytic effects. Y5 receptor antagonists are anxiogenic in rats
115, 119, 128

.
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Figure 6 - Representative G-protein Therapeutic potential of neuropeptide Y (NPY)
receptor ligands

Adapted from Wahlestedt et al., EMBO Mol Med 2010 65.
Figure 6. NPY receptors couple to the Gi signaling cascade. Agonist binding activates the
alpha subunit, which inactivates adenylyl cyclase. The beta/gamma subunit activates a
number of different kinase cascades. Activation of the G protein complex can also lead to
depressed Ca++ channel activity and enhanced G protein coupled inwardly rectifying
potassium (GIRK) currents. These cellular signaling cascades have effects on initiation of
gene transcription, and physiologic effects such as the stimulation or inhibition of
hormone/neurotransmitter release.
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Table 1. Relative distribution of NPY receptors in the CNS
(++++: very high; +++: high; ++: moderate; +: low; +/−: very low; −: undetectable.

Y2

Y1

Y4

Y5

Frontal cortex

++++

+

−

+/−

Lateral septum

+

++++

−

+/−

Lateral dorsal septum

++

++++

−

+

Nucleus accumbens

+

++

−

−

Bed nucleus of stria terminalis

+

++

−

+/−

Medial pre-optic area

+

++

++

+/−

+

++

+++

+

Lateral hypothalamus

+

++

−

−

Perifornical area

+

++

−

+/−

Arcuate nucleus

+

++

−

−

++

++

−

+/−

Dorsal hippocampus

+/++

++/+++

+/−

+

Ventral tegmental area

+

++

−

+/−

Central gray

+

+

−

−

Dorsal raphe

+/−

++

−

−

LC

+/−

+

+/−

+/−

Pontine tegmental nucleus

+/−

++

+/−

+/−

Nucleus of the solitary tract

+++

++

+++

++

Area postrema

++

++++

++++

+

Paraventricular nucleus

Amygdala

Adapted from Kask et al., Reviews, 2002 63.
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Figure 7 - Neuropeptide Y receptors subtype selectivity

Adapted from Pedragosa-Badia X et al., Frontiers Endocrinology, 2013 129.
Figure 7. Important amino acid positions and truncated peptides to introduce selectivity to
NPY receptors.
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Intranasal delivery of drugs to the brain
Effective treatments for psychiatric and neurodegenerative diseases have faced
many challenges due to the inability of therapeutics to cross the blood brain barrier (BBB).
The BBB is made up of endothelial cells and the microvasculature of cerebral tissue
essential in protecting against the crossing of neurotoxic substances and maintenance of
homeostasis within the central nervous system (CNS). The BBB restricts access to the
CNS limiting what can be transported into the CNS to small molecules such as lipophilic
compounds or to those that have expressed transporters such as glucose, leptin or ghrelin
130

. The intranasal route of delivery to the CNS uses both an extracellular and intracellular

pathway to avoid systemic circulation (Fig. 8). This delivery route engages the olfactory
receptor neurons (ORNs), trigeminal nerves, nasal and respiratory vasculature for direct
delivery to the brain 131, 132. Drugs delivered intranasally interact with the respiratory and
olfactory areas

133

of the nasal cavity. Both areas enable the transport of compounds

directly to the brain via the olfactory neurons. The absorption of molecules occurs at the
olfactory and respiratory epithelia

134

. The routes of compound transfer through the

olfactory area, of the nares, to the olfactory bulb are transcellular through either the
sustentacular cells or the exposed olfactory sensory neurons 134, 135. The route of transfer
to the trigeminal nerves goes through the nasal respiratory epithelium to the brain. The
drug is transported to the midbrain from the olfactory bulb or to the brain stem from the
trigeminal nerve which may occur via extracellular convective bulk flow

134

or through

perivascular routes 136. Dosed nanoparticles given by intranasal administration have been
found in the olfactory bulb 5- minutes after dosing 137 suggesting that the olfactory bulb
(OB) is the route of entry for nanoparticle delivery systems.
The Sabban laboratory has demonstrated that intranasal NPY administration to
rats reaches the CNS and periphery 30 minutes after administration (Table 2)
22

81

. The

delivery of NPY to specific brain areas was shown after infusion of fluorescent-labeled
NPY (FAM-NPY, Phoenix Pharmaceuticals). Various brain regions, including olfactory
bulbs, hypothalamus, hippocampus, locus coeruleus and the amygdala were labeled with
FAM-NPY 30 minutes after infusion (Figure 9).
Advantages of intranasal delivery include the ease of administration,
noninvasiveness, rapid onset of action and avoidance of effects on cardiovascular function,
gastrointestinal degradation and hepatic and extrahepatic degradation (first-pass
metabolism).
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Figure 8 - Intranasal Pathway Schematic

Adapted from Crowe TP et al., Life Sciences 2018 138.

Figure 8. Support cells (SC), olfactory sensory neurons (OSN), mucus-secreting
Bowman's capsule (BC), cribriform plate (CP), olfactory ensheathing cells (OEC),
olfactory nerve fibroblasts (ONF), subarachnoid space (SAS), and olfactory bulb (OB).
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Table 2. Concentration of NPY in CSF and plasma 30 min after IN NPY
administration

Nd = Not detected
Adapted from Serova et al., 2013 81.
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Figure 9 - FAM-labeled NPY Levels in Brain Regions within 30 min after Intranasal
Infusion

Adapted from Sabban et al., Neuropeptides 2016 80.

Figure 9. Fluorescence in various brain regions 30 min after intranasal infusion of FAMlabeled NPY. White arrows show selective labeled cells. Bar = 100 μm.
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Animal Models of Stress
Neuropsychiatric disorders such as PTSD, major depression, autism,
schizophrenia, major depression and bipolar disorder are very prevalent neurological
conditions 139, examples include: anxiety disorders 28.8%; mood disorders, 20.8%;
impulse-control disorders, 24.8%; substance use disorders, 14.6% and any disorder,
46.4%. Half of all lifetime cases start by age 14 years and three fourths by age 24 years
139

. These disorders have significant negative effects in society, which is coupled with

limited understanding of mechanisms and minimal development of effective
therapeutics. The challenge has been in part due to the gap in knowledge in the
pathophysiology of these disorders. Although there has been good progress made
towards the development of noninvasive technologies to study human brain structure and
function, a major challenge has been the ability to study the molecular mechanisms
underlying these disorders in the human brain. This limitation necessitates the use of
good animal models to recapitulate the disease as seen in humans that can have a good
predictive power for drug efficacy in human disease.
Requirements for disease animal models include using causative agents of
human disease to exhibit a significant degree of neural or behavioral pathology that
corresponds convincingly to the human disease 140. Several animal models of
neuropsychiatric disorders for autism, PTSD, major depression and schizophrenia. have
been generated by various methods such as genetic engineering, brain lesions,
environmental manipulations and ontogenetic manipulations of relevant brain circuits 141.
To determine whether an animal model is relevant to the specific disorders, it
needs to recapitulate the disease or core symptoms as observed in patients. Three types
of validators for a disease animal model include: construct validity, face validity, and
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predictive validity and has been used widely across many laboratories. In brief, construct
validity means that it measures what it intends to measure. The ability to recapitulate
important anatomical, biochemical, neuropathological, or behavioral features of a human
disease is known as face validity. However, there is no guarantee that an animal model of
a neuropsychiatric disorder that would recapitulate all of the behavioral features
observed in humans. Animal models cannot mimic psychiatric and somatic disorders in
their entirety however; assessing the impact of certain risk factors for the disorders in
animal models will facilitate the understanding of their etiology and treatment options in
patients.
Response to treatments that can predict the effects of treatments under
investigation in humans is known as predictive validity. Behavioral screens using these
animal models as a readout for disease symptoms to find drugs for therapeutic
intervention have been widely adopted. In our study, we used an animal model of stress,
the single prolonged stress animal model (SPS) to recapitulate some of the PTSD core
symptoms as seen in patients.
Stress leads to a plethora of many reactions that engage our physiological
systems. Various parameters can be utilized for monitoring stress response in animal
stress models, these include stress phenotypes and changes that occur during or after
each stressor and these should be well characterized.
Chronic or repeated stress is the leading cause of many psychiatric disorders
such as major depressive disorder, anxiety disorders and cardiovascular diseases.
Although therapeutic agents have been developed to treat stress-related disorders
however, they have not been sufficiently effective as many patients often report
persistence of core symptoms and side effects. This has put a higher demand on basic
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research to search for underlying mechanisms of stress related disorders and effective
treatments. Several animal stress models have been developed to study stress related
diseases in humans and the development of new drugs.
Single prolonged stress (SPS)
Single prolonged stress (SPS) is a multimodal traumatic stress exposure protocol
142

. SPS consists two hours of restraint, twenty minutes forced swim, followed by exposure

to ether until loss of consciousness followed by a 7 or 14-day undisturbed period. This
protocol is carried out in a single session to cause a robust stress response and elicits a
negative feedback of the HPA axis seven days after SPS stressors. Animals exposed to
SPS (Figure 10) have many PTSD-like symptoms as seen in patients. This method is
reproducible and produces behavioral and neuroendocrine effects similar to those observed
in animals exposed to comparable stress protocol 143. The core symptoms of the SPS model
and the time course of PTSD-like progression in these rodents is similar to the impaired
neuroendocrine response in PTSD patients 14, 94.
The SPS animal model has been used widely to study behavioral changes, molecular
adaptations and neurobiological processes and thus meets the construct and face validity
requirement. As a requirement, animal models of post-traumatic stress should recapitulate
the disorder and elicit behavioral changes similar to those observed in PTSD patients 144.
The SPS animal model uses a single episode of traumatic stress to evoke persistent
behavioral changes comparable to the PTSD core symptoms of anxiety, depressive-like
behavior and hyperarousal which are all responsive to PTSD treatments up to three weeks
after exposure to SPS 78, 81, 82. The ability of the SPS animal model to respond to treatments
indicates that it meets the predictive validity requirement. Therefore, based on the
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numerous and robust studies done using the SPS model and its reproducible nature, we
chose this model to study PTSD in rats.
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Figure 10 - SPS Schematic

Adapted from Souza et al., Front. Pharmacol. 2017 145.
Figure 10. Single prolonged stress (SPS) procedure and SPS-induced behavioral changes.
(A) Timeline of SPS procedure. On a single day, rats are subjected to a 2-h immobilization
followed immediately by a 20-min forced swim. Rats are given a brief period of
recuperation and then subjected to diethyl ether until they are anesthetized and
unresponsive. (B) Behavioral changes observed up to 1 day later. Anxiety, arousal, spatial
memory, and fear learning are unchanged. Acute increase in REM sleep and transition to
REM sleep is observed. (C) Behavioral changes 1 week later. Anxiety, arousal, fear
context discrimination, and fear learning are increased. On the other hand, extinction,
spatial memory, social interaction, and recognition memory are decreased a week after
SPS. (D) Behavioral changes following re-stress. Enhanced anxiety, arousal, fear learning,
and sleep disturbances remain observed following re-stress, while extinction and spatial
memory are impaired. Green, red, and yellow arrows indicate no “changes observed”,
“increase”, and “decrease”, respectively.
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Methods
Animals
Male Sprague–Dawley rats from Charles River (Wilmington, MA, USA) were
used in all experiments. They were housed on a 12 h light/dark cycle at 23 °C with
unlimited food and water. Animals (150–160 g, 4 per cage) were allowed to acclimatize
for 7 or 14 days and were assigned randomly to experimental or control groups.
All experiments complied with ARRIVE guidelines and were performed in
accordance with the NIH Guide for Care and Use of Laboratory Animals and approved by
Institutional Animal Care and Use Committee at NYMC and the USAMRMC Animal Care
and Use Review Office.
Single prolonged stress (SPS)
Animals were exposed to modified SPS stressors 142 between 9 AM and 2 PM as
previously described (Serova et al., 2013). They were immobilized for 2 h by tapping limbs
to a metal board, which also restricts motion of the head. This was followed immediately
by a forced swim for 20 min in a plexiglass cylinder (50 cm height, 24 cm diameter,
Stoelting, Wood Dale, IL, USA) filled two-thirds with 24 °C fresh water. After the forced
swim, animals were dried and allowed to recuperate under heat lamp for 15 min and
immediately exposed to ether vapor until loss of consciousness. Afterwards, animals were
housed two per cage and left undisturbed for 7 or 14 days.
Intranasal infusion
Rats were given intranasal infusion of 150μg and 300μg NPY or 150 μg [DHis26]NPY or 150μg NPY (3–36) or 150μg [Leu31Pro34]NPY freshly dissolved in 20μl
distilled water or the vehicle alone under light isolfluorane anesthesia or ether if at the end
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of the SPS stressors. Each rat received 10μl into each nostril, and the head kept titled
backwards for an additional 15s.
Elevated plus maze (EPM)
Anxiety behavior was tested on the elevated plus maze (EPM) apparatus (Stoelting,
Wood Dale, IL) as previously described (Serova et al., 2013) and videotaped. Analyses of
all behavioral measurements were performed in a room with dim light setting and animal
were allowed to accommodate for 30 minutes in the room. The maze is 40 cm above the
floor, has cross-shaped platforms with two open arms with 2 cm high walls, and two closed
arms with 40 cm high opaque walls. Rats were placed on the central platform facing an
open arm and allowed to explore the maze for 5 min following 30 min acclimation to a
room with dim light. Behaviors were recorded and analyzed using tracking software
“Viewer 3.0” with a designated “Plug-in” program (Biobserve, Bonn, Germany).
Entry into the open (OA) or closed (CA) arm was defined as entering with all four
paws. Anxiety index was calculated as 1- [(time spent in OA/total time on the maze)/2 +
(number of entries to the OA/total number of entries into OA and CA)/2]. Risk assessment
was evaluated by the rat poking its head or trunk into an OA while its hind quarters were
located in one of the CA. Animals were put in the EPM by an individual blinded to the
treatment group. Scoring were done by more than one person that was blinded to the
treatment groups. Percent maximal anxiety of one was calculated by X (max anxiety) = #
of rats with index 1 x 100% / # of all rats.
Forced swim test (FST)
Immobility time in the forced swim test (FST) was carried out as previously
described (Serova et al., 2013) to assess depressive/despair-like behavior. After 30 min
accommodation, rats were placed into a plexiglass cylinder (50 cm high, 24 cm diameter)
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filled two-thirds with 24 °C fresh water for 5 min and the behavior videotaped. The water
was changed between animals. Time spent immobile was defined as the animal showing
no movement of any of the four limbs, or only floating movements needed to keep its head
above the water for 5 minutes of swim duration.
Social interaction (SI)
The SI test was performed in a room with dim light. One day prior to SI test,
animals were allowed to explore an open field (75 cm × 75 cm × 35 cm) for 10 min in
order to reduce anxiety component of the novel environment. On the next day, rats were
acclimated to the room for 30 min and then allowed to explore the field for 5 min before
and 5 min after the introduction of a naïve juvenile rat. The behavior was videotaped and
the number of approaches calculated.
Acoustic Startle Response (ASR)
To assess hyperarousal symptoms, ASR was measured in a sound-proof chamber
(SR-LAB) (San Diego Instruments, San Diego, CA, USA) as previously described

79, 81

.

Animals were placed into a cylindrical enclosure designed for rats containing a platform
connected to a piezoelectric accelerometer. The steadiness of the piezoelectric
accelerometer was calibrated using a stabilimeter for consistent sensitivity among the
chambers and over time. Sound levels within the test chambers were measured with a
detachable probe sound level meter to ensure consistent presentation. After a 5 min
accommodation period with white noise of 68 dB, animals were exposed to 10 repeats of
100 and 115 dB trials for 40ms (total 20 trials) in random order with inter-trial intervals
from 30 to 38 s. Voltage data were transferred to a computer using an automated software
package (San Diego Instruments). The cylindrical enclosures were cleaned with soap and
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water between animals. To analyze data, ASR of animals after single prolonged stress
(SPS) were compared to their basal ASR.
Tissue Isolation
Animal were euthanized by decapitation. Brains were dissected used a brain
matrix. Sections containing the LC were dissected according to the coordinates 9.2
−10.4 mm posterior to bregma and placed immediately in cold PBS. LC was identified by
using reference structures such as the 4th ventricle. A glass pipet with a < 1mm diameter
was used to punch out the LC and transferred to an eppendorf tube, which was flash frozen
in liquid nitrogen and stored at -80oC until used. The mediobasal hypothalamus, without
arcuate nucleus were also isolated immediately following euthanasia of animals. All
experimental group of animals including the unstressed controls were treated the same and
the surgeon was blind to the experimental groups.
Determination of mRNA levels in the mediobasal hypothalamus and the LC
The RNeasy Mini Kit (Qiagen, Valencia, ML) was used to isolate total RNA and
concentration was determined using NanoDrop 2000 (Thermo Fisher Scientific,
Pittsburgh, PA). RevertAid First Strand cDNA Synthesis kit (Thermo Fisher Scientific)
using an oligo dT primer was used in the reverse transcription of 600 ng of LC RNA and
1000 ng of mediobasal hypothalamus RNA. The cDNA (2 µL) was mixed with 12.5 µL
of FastStart Universal SYBR™ Green Master Rox (Roche Diagnostics, Indianapolis, IN)
and 1 µL of one of the following primer sets from Qiagen; (NET, PPRO6785A-200);
(NPY, PPR44428A); (Y1R, PPR56359A), (Y2R, PPR06816A); (Y5R, PPR449006A);
(Crh, PPR44803B); GR (NR3c2, PPR52805B); (Fkbp5, PPR51629B); (Crhr1,
PPR44886F);and glyceraldehyde‐3‐phosphate dehydrogenase (Gapdh) forward and
reverse

priers

respectively:

5’

TGGACCACCCAGCCCAGCAAG
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3’;

5′‐

GGCCCCTCCTGTTGTTATGGGGT‐3′ to a final volume 25 µL. Reactions were run on
a real‐time PCR instrument (Applied Biosystems, Carlsbad, CA) and data were analyzed
using QuantStudio™ Design & Analysis Software v. 1.4.1. Data were expressed as the
relative fold changes calculated using the ΔΔCt method after normalizing to reference gene
GAPDH. The main criterion for a gene to qualify as a reference gene is a stable expression
across various cell and experimental settings. GAPDH is a widely used internal control in
PCR 146, 147. GAPDH can also be used alongside other internal controls such as tubulin and
beta-actin to assess if GAPDH expression is differentially expressed between similar
samples.
Western Blot Analysis
Total protein from selected brain regions was isolated by homogenization in RIPA
buffer. Protein concentration was determined by DC Protein Assay (Bio-Rad) with BioTek plate reader. Briefly, 10 μg of total protein were separated on 4%–15% Tris-HCl
gradient precast gels (Bio-Rad) and transferred to nitrocellulose membranes (Bio-Rad).
After blocking in Tris-buffered saline (TBS) containing 5% dry milk and 0.1% Tween 20
(TBS with Tween 20 [TBST]), membranes were incubated with primary anti-NET (Abcam
41559) overnight at 4°C. After incubation with secondary anti-Rabbit (IRDye 800CW)
signal was visualized using the Odyssey Infrared Imaging System (Li-Cor) and analyzed
using IPLab software (BD Biosciences). NET protein levels were normalized to GAPDH.
Anti-GAPDH (14C10) was obtained from Cell signaling (Catalogue no. 2118).

Statistical analysis
Data were analyzed using GraphPad (Prizm8, La Jolla, CA, USA) by t-test or oneway analysis of variance (Anova) followed by Tukey's Multiple Comparison Test. The
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distributions were analyzed by the Anderson-Darling test for normality and nonparametric Kruskal-Wallis test. When the distribution failed the test of normality and
indicated two subgroups, the values were divided based on the mean of the unstressed
control before further analysis. Outliers were removed when they were greater than two
standard deviations away from the mean. Outliers can arise from low quality of tissue
samples or a compromised or sick animal. Values at p≤0.05 were considered significant.
DNA methylation studies

DNA Isolation
Genomic DNA was isolated from the LC using the DNeasy kit from Qiagen.
Tissues were kept rocking at 55°C in 500 μL of tissue lysis buffer (100 mM Tris at pH
8.5, 5 mM EDTA, 0.2% SDS, 200 mM NaCl) with 100 μg/mL proteinase K overnight.
Digestion was followed by vortexing and centrifugation according to the step-by-step
protocol from the DNeasy kit from Qiagen. DNA was recovered and re-suspended in 18
μL of dH2O. To determine DNA quality, eluted DNA was run on 0.9% agarose gel.
Genome Assembly:
Gene
Slc6a2

chr
chr19

rn6
start

end

15391682

15431274

gene
Slc6a2

strand
-

We chose the 2000 bp sequence upstream the TSS and 1000 bp downstream the TTS, and
predicted the CpG Island. Our prediction is shown in the below figure and table (the red
curve is the GC content, the green curve is the O/E value, and the yellow box represents
the CpG Island).
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Slc6a2
No.
STAR
LAST
Length
GC_Contents
obs/exp_CpG_ratio
T735
1
1863
1129
64.48
0.66
CpG regions sequenced relative to promoter start site are region 1(slc6a2-1) -1199 t0 -947
and region 2 (slc6a2-2) -339 to -614
NET Promoter Sequence:
>Slc6a2:chr19:15430274-15433274:+
CCCTTCAGAAAGGAGCCCGAGTCTACCTCCGTGGTGCTGTATGTGGCCT
GTGGGTTCATTCCAGAGCAGATGGGTAAAATGACAGCTCATCACGAAGA
GGACAAAAGG
GCTTGTCTGCTTGGTGTCTTCTCCAGGCTTGTATGCACTGGGCTTCACAA
CTTGGCCAGAGCTTGCAAAGCTAACAAGGACACTCCAGTCCCCAGGAGT
GCCTCAAGG
TCCCATTCAGCTCTTGGCATCCAGTATCCTGATCTCATGAAAGCTGTGTA
CACTTACCCCTGTAGCCCGCTGAGGATCCAAGGGCTCTCATTTTATCCAG
CCTAACGC
CTGAGCTCCAAGGTTGAGTGCTAGAATTATCGTCAAATCTTGTGTCTTGA
CTGGAACATCCCAAACTTTTCTCTACTCCCTTTTCTGCGTCACAGCATTG
ACTCTGAG
TCCCTGGCCCGACCAGATGCCTTCTATGCTGTCCCTGAGCCCTTGTGCCT
ACTACTATTCAAGGTTCTGCCTCTATTTCCCTAACAGAAACTACCCAGAT
CCTTTTTC
TCAGTACCCTTAAGAGTTCTTTCCTGCACACAAAATTTTTTCTGTGTCTCC
TCTTTTCCTCCATGTGCATCCCTGCTCCCTCCCCAGACAATGCCACAAGA
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ACAGGCA
GCATCCCAAAAGCTTCAGCCAACCCTGTGCTCACCACCACCATTCTTGTA
GCAGAGATAGGGGAAGCGCCACACATTGGCCAGGTCCACTGCGAAGCC
CACCACAGAC
AGCAGGAAATCAATCTTCTTGCCCCAAGTCTCCCGGGGCTGCGCGTCAC
CATCCTGGGATGCCAGGAGACACTGGACGCCGTTGTGCTCCTTCACCAC
TAGCAGATCG
GCGGTTTTGCAGGGCCTCAGGGGCTGCTCGGGCAGCTGGTCCGCCCCGC
CGAGCTCAGGCTGCACCTGCGGCTTCATTCGTGCCAGAAGCATGGGTGC
GGCTGGAGAG
AGGGACTTCGGAGGCACTGGGGACACACCAAAGTTCAAGTTCTGCTCGT
ATGAAAGGAGAAAAAGCAGTCAACAAGGCTTGCCTCCCGTTTGCACCAA
CTGAGACCAC
CCAAGGGAACCCAGATGTCAGGATCCGTGCGCTGAGCGGACTCAGGCTT
CCTAGAAAAGGAGTGCCTGAGTTGGGAATTTTTGGACACTAAGGTTGTG
ACGTGCGTCC
GACTGGGACAGAATTTATAGGTGGGGACCTCCTCGGGCCGCCCTGTGGG
TCGGGCTAAAGACCCCGCCGAGGTCTACCTGGGTCATTCACTGTCCCCTC
CCCTTCCCT
AAATGCCAAGTTTCTTGCGGGCCCTGAGGGACCGAAGTTGACTGGAGGC
CCCTATCCAGCTCCGGGGAACGCCCTCCGACAGCACTAGGAGCCTTTGG
GGACACTCTA
GAGGGTGCAGCCGCTCACGATGTGCCTCGGAGCCGGTCTGCACACTTAC
CGGTCCCGCGCGCACAGAGCGCACTCACGTGGCGGACAGCACGGGGAT
CCCGGGCTCCA
GCCGGGGCTGGGGCTGGGCTCCGCCGCGTGGCACTCAGGCGGGGCCCGG
GAGCGCTGCGGGGACGGGGTGGCCGGCAGGACGCGGGCTGGCTGGCTC
TGGCCGCGCCA
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GGAGGAGGCCGACCTGGTAATGTAGCCTGTGCCCCAGGTAACGCGCCTA
TTGCATTAGCCCCGCGCCCAGCCCGCTCGGTCTGGAGCCTGTTAGCGCTA
ATGCAGACT
GACAGCGTGGCCGGGACTGGCAGAGGCGGGGGCGCAGCTCCCAAGGGC
TCCGGGGTGGCGGGTGCCGGACTCTCAGAGACTCGGGGGATCTGGCTTA
GCACCCTTTCC
AGGCTGCTCCCCAAAACACCTGGCTCTGACCTCTGGACAGAGGAAGAGA
GCAACAGATTCCCAGAACTCCCAGAAGTCTGTCAAAGGGGAGTTGTAAA
GACACAGGGA
AGCAGTCACCACCCCAGTGACACCAGCATTGTCATACACCCAAGCCACT
TAACCTACTTGGTGAGAGTTTTCTCCACCAGCAGAATGGGAACTTAGTG
CTCCGAGATG
AAGACTGTGACTGGTGGCCTGCAGGCTCGGCCTTTTGGGTAGTTTTGTTT
GGCCGGCTCTGCTGGTTGAAAGGTCATAGACAGATTTTACTCCTGGCTCC
ATTTGTGA
CCAGGCTGTGACCTTGATCTTGGGGTCTGTGGCCCTGATCTATAAGGCTG
AGAACTGATACCCACTCGTTCTCAAAAATGCTCCCCGTATGCCAAATCA
AGCCTTTTT
AGTTTCCCACTAGTGGACGACACCTTCAAAGAGCCGGTTGTTTGGTCCCG
GAAACAGGAGGGAAACAGGAAACACAATAAATAAATACTTATTACTCA
CTCGTGTGGT
ATGGACTGGGGGCGGGTAAAGCAAAGTAAGAAAATGGATGGAAAAAGC
AAAGTAGGGCTGCACATTTTTAACAATATGTTCTATAGTGTTTAAGCATG
AACTACTTG

ACCTGAGAGTTTACTTACCCAACTTCTTGTGTCTGAATCAACCCTGAAAGG
AAGATCGCAGAGACAATCCCAGACACCCAGTGTGCAAAGAGCTTACCGCC
CTTAGAA
40

CTGCTTGTGGTCATAGGAGAACAGGACTTTGGGGAAGCCAAATTAGTAAG
GTCAGCAGGCAGGAATGTAGGGAAGACACAAAACAGTACGGGAAGACGC
TTAGATAAG
CCTAGCCGCACTGATCTTTCTACACTTTCAACATTCCAAGCTCAAAGCTAC
CCATGGGCACTTGCATTAGCTCTGACTTCCATCTAAGTTGTTCAGGTCTTA
GTGAAG
ATATTCCTTCTTAGACTTGTGCATCTAGAAGTCGCCCCCATCCTCCATCAG
ATCACTGATGCAATTTATTAATTATTAATTAATTAATAATTGATTAATTGAT
TAATAATTGATCTCCC
TTTTAGTGGCAGTTGAGCTCTAGAAGAACCAAGTATTGTCTACCTTATCCA
CCTGTGTCTCTGGCACTAGAACTCACTAAACACT
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DNA Library Preparation was performed by CD Genomics, (Shirley, New York).
In brief, gene-specific DNA methylation was assessed by a next generation
sequencing-based bisulfite sequencing PCRs (BSP). In brief, BSP primers were designed
using the online MethPrimer software. Genomic DNA (1 ug) was converted using the
ZYMO EZ DNA. Methylation-Gold Kit (ZYMO) and one-twentieth of the elution
products were used as templates for PCR amplification. For each sample, BSP products of
multiple genes were generated, pooled equally and subjected to adaptor ligation. Barcoded
libraries from all samples were sequenced on the Illumina Hiseq platform using pairedend 150 bp strategy.
Primer Sequence for two CpG regions in the NET promoter

Amplicon Sequence Information
Slc6a2-1 (Region 1)
5’GTCACCATCCTGGGATGCCAGGAGACACTGGACGCCGTTGTGCTCCTTCAC
CACTAGCAGATCGGCGGTTTTGCAGGGCCTCAGGGGCTGCTCGGGCAGCTGG
TCCGCCCCGCCGAGCTCAGGCTGCACCTGCGGCTTCATTCGTGCCAGAAGCA
TGGGTGCGGCTGGAGAGAGGGACTTCGGAGGCACTGGGGACACACCAAAGT
TCAAGTTCTGCTCGTATGAAAGGAGAAAAAGCAGTCAACAAGGCTTG---3’
Slc6a2-2 (Region 2)
5’AGCCTTTGGGGACACTCTAGAGGGTGCAGCCGCTCACGATGTGCCTCGGAG
CCGGTCTGCACACTTACCGGTCCCGCGCGCACAGAGCGCACTCACGTGGCGG
ACAGCACGGGGATCCCGGGCTCCAGCCGGGGCTGGGGCTGGGCTCCGCCGC
GTGGCACTCAGGCGGGGCCCGGGAGCGCTGCGGGGACGGGGTGGCCGGCAG
GACGCGGGCTGGCTGGCTCTGGCCGCGCCAGGAGGAGGCCGACCTGGTAAT
GTAGCCTGTGCCCCAGGTAA---3’
Next generation sequencing-based bisulfite sequencing PCR (BSP)
Gene-specific DNA methylation was assessed by a next generation sequencingbased BSP, according to previously published method
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. In brief, BSP primers were

designed using the online MethPrimer software. 1 μg of genomic DNA was converted
using the ZYMO EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, CA, USA) and
one-twentieth
of the elution products were used as templates for PCR amplification with 35 cycles using
KAPA 2G Robust HotStart PCR Kit (Kapa Biosystems, Wilmington, MA, USA). For each
sample, BSP products of multiple genes were pooled equally, 5'-phosphorylated, 3'-dA-
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tailed and ligated to barcoded adapter using T4 DNA ligase (NEB). Barcoded libraries
from all samples were sequenced on Illumina platform.
For the bisulfite sequencing reads of each sample, firstly, adapters and low-quality
reads were removed using software Trimmomatic-0.36 software
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essentially has a

variety of processing steps that removes low quality sequences such as adapter sequences,
primer fragments that could result in suboptimal downstream analyses. After removing the
adapter sequences and filtering out the low quality reads, the clean sequencing reads were
directly aligned to the target sequences using software Bsmap (v2.73) with the default
parameters, which combines genome hashing and bitwise masking to achieve fast and
accurate bisulfite mapping. Methylation levels are defined as the fraction of read counts
of ‘C’ in the total read counts of both ‘C’ and ‘T’ for each covered C site. On the basis of
such read fraction, methylated cytosine was called using a binomial distribution as in the
method described by Lister et al. 148 whereby a probability mass function is calculated for
each methylation context (CpG, CHG, CHH). Two-tailed Fisherʼs Exact Test was used to
identify cytosines that are differentially methylated between two samples or groups. Only
those CG covered by at least 200 reads in at least one sample were considered for testing.
P-value thresholds were selected such that the level of Significance is less than 0.001.
Statistical analysis
The methylation level of the CG on each target sequence of each sample was
calculated. The methylation level is calculated as follows: methylation rate of C site =
100* supports for
methylation reads/ (supports for methylation reads + support for unmethylated reads). The
level of methylation in each sample at each site was calculated, the significance of the
differences between the sample groups was based on the methylation level of each
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site.

The

average

level

for

each

CpG

locus

were calculated from

(methyl_C/(methyl_C+N_methyl_C), the methyl_C means number of reads that have
methylated CpG

while the N_methyl_C means the number of reads that have non

methylated CpG. Data were analyzed using GraphPad (Prizm8, La Jolla, CA, USA) by ttest.
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Results
Measure of anxiety on the elevated plus maze (EPM) one or two weeks after SPS
stressors
Anxiety behavior is a core PTSD symptom that can last for a lifetime. Anxiety
symptoms have delayed onset and might not manifest immediately after the trauma. It has
been shown that evaluating the biological progression of PTSD and comorbid impairments
using a staging approach is necessary to understand the underlying mechanisms of the
disease 5. To evaluate the progression of anxiety symptoms in the SPS animal model of
PTSD, two cohorts of animals were placed in the EPM and behavior was assessed one and
two weeks after SPS.

Acclimatization SPS
2 weeks

1 week
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Cohort
1

Cohort
2

EPM

EPM
2 weeks

Progression of anxiety-like behavior

Figure 11. Anxiety index at one or two weeks after SPS. A. Percentage of entries into the
open arms (OA) of the EPM. B. Percentage of time in the OA of the EPM. C. Anxiety
index; each data point represents an individual rat with mean (horizontal line). *p < 0.05,
**p < 0.01, ***p <0.001 compared to Controls; #p < 0.05, ##p < 0.01, ###p <0.001 for
SPS/1 wk vs SPS/2wks. D. Percentage of animals with maximal anxiety index (1.0) pooled
from three separate experiments. Each point represents values for individual animal.
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There was a worsening of anxiety-like behavior at two weeks (11A-C). ANOVA showed
significance in the percent of entries into the OA (F = 18; p < 0.05), duration in the OA
(F = 14; p < 0.001) and the anxiety index (F = 6; p < 0.001). Tukey comparison of the
means revealed that all SPS groups had fewer entries and lower duration in the OA and
higher anxiety index compared to controls (p<0.001) in Figures 11A and B. The SPS
groups after SPS stressors differed in the OA entries and duration (p < 0.001; p <0.05) and
anxiety index (p < 0.01) at one week compared to two weeks. This result revealed a
progressive worsening of anxiety like behavior in the SPS animal model indicated by the
increase in the number of animals with maximal anxiety index of 1 at two weeks compared
to one week in Figure 11C.
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Reversal of anxiety, depressive-like behavior and hyperarousal two weeks after
SPS stressors by intranasal NPY

Previously Dr. Sabban’s laboratory showed that intranasal NPY prevented
development of PTSD symptoms and also reversed symptoms when intranasal NPY was
administered one week after SPS. Here, we wanted to evaluate the ability of intranasal
NPY to reverse SPS-triggered impairments in anxiety and depressive-like symptoms
manifested two weeks after SPS stressors when symptoms are more severe (Fig. 11).
Animals exposed to SPS were treated with 150 µg /rat of NPY since this dose was
previously shown to be effective in reducing SPS-elicited anxiety one week after SPS
stressors (Serova et al., 2014a). To our surprise, intranasal administration of 150 µg /rat of
NPY did not reverse anxiety symptoms manifested two weeks after SPS stressors when
symptoms are more severe, subsequently we doubled intranasal NPY dose to 300 µg /rat.
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Reversal of anxiety-like behavior by NPY

Figure 12. Effect of intranasal administration of NPY to reverse symptoms of anxiety on
the EPM. A. 150 µg/rat of NPY (SPS/NPY) or vehicle (SPS/V) two weeks after SPS
stressors compared to unstressed controls (Controls). B–D Rats were administered
300 µg/rat of intranasal NPY or vehicle 2 weeks after SPS stressors and tested on EPM
for: B. entries into open arms; C. time in

open arms and D. anxiety index. *p < 0.05,

**p < 0.01, ***p <0.001 compared to Control; #p <
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0.05, ##p < 0.01, ###p <0.001 for SPS/V vs SPS/NPY. Each point represents values for
individual animal.
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Intranasal NPY dose of 150 µg /rat was previously shown to be effective in reducing SPSelicited anxiety behavior one week after SPS stressors (Serova et al., 2014a) however,
intranasal administration of 150 µg /rat of NPY was not sufficient to reverse anxiety
symptoms manifested two weeks after SPS stressors (Figure 12A) . One-way ANOVA
(F = 7.2 p < 0.003) was significant for percent of entries into the OA. There was no
difference in percent entries to the open arms in rats given vehicle or NPY, and both groups
had less entries to the OA compared to the unstressed controls.
The dose of intranasal NPY was doubled to 300 µg /rat in a different cohort (BD) and anxiety-like behavior was assessed on the EPM two days later. One-way ANOVA
revealed significant effect of treatment on entries into OA (F = 20.5, p < 0.0001, B); time
spent in OA (F = 6.7 p < 0.01, C) and anxiety index (F = 19, p < 0.001, D). The NPYtreated rats behaved similarly to the unstressed controls in the number of entries to the OA,
time spent in the OA and anxiety index.
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Figure 13
Effects of NPY on Risk Assessment and Locomotion

Figure 13. Effects of intranasal administration of NPY on risk assessment: number
of head dips and locomotion: total distance travelled on the EPM. In A-C, rats were
administered 300 µg/rat of intranasal NPY or vehicle 2 weeks after SPS stressors
and tested on EPM. A. Frequency; B. duration of risk assessment on the EPM and
C. Locomotion. Each data point represents an individual rat with mean (horizontal
line). *p < 0.05, **p < 0.01, ***p <0.001 compared to Control; #p < 0.05, ##p <
0.01, ###p <0.001 for SPS/V vs SPS/NPY.
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Infusion of 300 µg/rat of intranasal NPY treatment also increased frequency
(F = 8.4, p<0.001, Fig. 13A) and duration (F = 6.7, p<0.05, Figure 13B) of risk assessment
to levels similar to controls (p < 0.05, Figures 13A and 13B). There was a significant
difference in locomotor activity as measured by track length on the EPM
(F = 3,2, p<0.05, Figure 13C). Unstressed controls traveled longer distance than the SPS
vehicle group as expected. Administration of intranasal NPY did not have a significant
effect on the locomotion.
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Figure 14
1.2.3 Reversal of Depressive-like behavior in the Forced Swim Test by NPY

Figure 14. Reversal of depressive-like symptoms. A. 300 µg/rat of intranasal NPY were
administered to rats (SPS/NPY) two weeks after SPS or vehicle (SPS/V), two days
afterwards they were tested on EPM. Rats were then subjected to the forced swim test
(FST) two days after EPM. Each data point represents an individual rat. **p < 0.01;
Control; #p < 0.05.
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As shown in Figure 14, 300 µg/rat of intranasal NPY had a protective effect
against depressive-like behavior by reducing the immobility time in the FST. One-way
ANOVA (F = 7.1, p<0.01) was significant for the FST. The SPS/V group spent more time
immobile compared to the unstressed controls. Tukey multiple comparisons of the means
revealed significant differences between the SPS/V group and controls (p <0.01) or the
SPS/NPY (p<0.01) group.
Results presented here demonstrate a time-dependent progression in the
development of anxiety symptoms in the SPS model of PTSD. Severe anxiety, as indicated
by limited duration and entries into open arms of EPM and high anxiety index, was much
more pronounced at two weeks, compared to one week following the traumatic stress,
suggesting a worsening of symptoms. Doubling of the dose that was previously shown to
be effective one week following SPS stressors (150 µg /rat) was necessary to reverse
anxiety and immobility on the FST two weeks after SPS.
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Reversal of Hyperarousal Symptoms in Acoustic Startle Response by NPY
Startle response consists of a brief reflex twitch of somatic muscles in response
to a sudden, intense stimulus such as a sharp noise, that is dependent upon brainstem
cochlear nuclei, the caudal pontine nucleus, and spinal motor neurons

150-152

. Poor

extinction and abnormal acoustic startle response (ASR) has been shown to be associated
with PTSD, thus potential predictors of the development of PTSD-like behavior. Here,
we evaluated if intranasal administration of NPY can reverse hyperarousal symptoms and
how long such reversal can be sustained.
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Figure 15
Acoustic startle response (ASR)

Basal ASR
SPS
Acclimatization
2 weeks

1 day

IN NPY or Veh
2 weeks

ASR

3 days

Figure 15.
Reversal of hyperarousal symptoms. A. 300 µg/rat of intranasal NPY were administered
to rats (SPS/NPY) two weeks after SPS or vehicle (SPS/V), three days afterwards ASR
was measured. Each data point represents an individual rat. ***p < 0.001; Control; ###p
< 0.001.

Administration of intranasal NPY reversed hyperarousal symptoms. Two weeks
after exposure to SPS, rats were administered either intranasal 300 µg NPY/rat (SPS/NPY)
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or vehicle (SPS/V) and three days later ASR was measured. One-way ANOVA revealed
significance in ASR (F = 18.6, p<0.001). The SPS group that received vehicle treatment
had an elevated startle response (p<0.001), while those given intranasal NPY had ASR
levels similar to the basal pre-SPS levels and lower than those only given vehicle (p<
0.001).
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Figure 16
1.2.5

Sustained Reversal of Hyperarousal Symptoms in Acoustic Startle
Response by NPY.
Figure 8

Basal ASR
Acclimatization

2 weeks
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SPS

1 day
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2 weeks
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ASR-1

7 days
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ASR-2
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Figure 16. Sustained reversal of ASR by NPY. (A) Two weeks after SPS stressors, rats
were given intranasal administration of 300 µg NPY or vehicle and ASR measured 7 days
after NPY infusion. ASR after SPS was normalized to the basal ASR for each animal and
the ratio (ASR/Basal ASR) is plotted. (B) A second infusion was given after the first
infusion in the same cohort and ASR measured 3 days later (eleven days after the first
NPY administration). ASR after second infusion was normalized to the basal ASR for each
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animal and the ratio (ASR/Basal ASR) is plotted. Each point represents values for
individual animal. *P < 0.05, **P < 0.01.
Intranasal NPY sustained the reversal of the SPS‐triggered rise in ASR. NPY
reduced ASR seven days after its first administration (16A) shown by a lower startle
response (t (19) = 2.3, P < 0.05) compared to the vehicle treated group (SPS/V). In addition,
we assessed the effect of a second infusion of NPY (16B) and found that NPY indeed
sustained the decrease in acoustic startle response 11 days after the first infusion (t(22) =
2.1, P < 0.05).
In summary, the ASR results demonstrates that doubling intranasal NPY was
sufficient to reverse the SPS‐elicited rise in startle response and hyperarousal symptoms
and maintained basal arousal levels for more than 1 week..
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Effect of Selective NPY receptor agonists on development of SPS triggered
impairments
Experiment design for agonists
The neuropeptide Y (NPY) mediate its effects via several G-protein coupled
receptors to proffer resilience to the harmful effect of stress in post-traumatic stress
disorder (PTSD). To investigate the role of individual NPY receptors in the resilience
effects of NPY to traumatic stress, intranasal infusion of either Y1R agonists [DHis26]NPY, [Leu31Pro34]NPY, Y2R agonist NPY (3-36) or NPY was administered to male
Sprague-Dawley rats immediately following the last stressor of the single prolonged stress
(SPS) protocol. We assessed effects one-week post SPS because we have determined that
at this time point PTSD symptoms in the SPS animal model are not as severe. When
efficacy is observed for a particular agonists one week after SPS, we would test the
effectiveness of the agonist two weeks after SPS when symptoms have become more
severe.
Dosing concentrations: NPY generally has a high affinity to Y1R, Y2R and Y5R.
The affinities of [D-His26]NPY, [Leu31Pro34]NPY, and Y2R agonist NPY (3-36) for Y1R,
both Y1R and Y5R and Y2R respectively are similar to NPY affinities (Table 6). We
began by using a similar dose that have been proven effective with NPY. Future
experiments will utilize a dose dependent approach in consideration of receptor affinities
to further determine the most efficient doses for optimal effectiveness.
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One-week post SPS
Experiment 1. The scheme of experiment is shown in Figure 17A. Rats (n = 12 per group)
were infused intranasally with either [D-His26]NPY (150 μg/rat) (D-H) or NPY
(150 μg/rat) or vehicle immediately following the last stressor (ether) of the SPS protocol.
Animals were left undisturbed for 7 days and behavior on EPM and FST were assessed
afterwards.

Figure 17A
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Experiment 2. The scheme of experiment is shown in Figure 17B. Rats (n = 10 rats per
group) were infused intranasally with either [Leu31Pro34]NPY (150 μg/rat) (LeuPro) or
NPY (150 μg/rat) or vehicle following the last stressor (diethyl ether) of the SPS protocol.
Animals were left undisturbed for 7 days and behavior on EPM and FST were assessed
afterwards.
Figure 17B
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Experiment 3. The scheme of experiment is shown in Figure 17C. Rats (n = 12 rats per
group) were infused intranasally with either the Y2R agonist, NPY(3–36) (150 μg/rat) or
vehicle immediately following the last stressor (diethyl ether) of the SPS protocol.
Animals were left undisturbed for 7 days and behavior on EPM and FST were tested
afterwards.

Figure 17C
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Two weeks Post-SPS
Experiment 4. The scheme of experiment is shown in Figure 17D. The rats (n = 12 rats per
group) were infused intranasally with either NPY (150 μg/rat), or [D-His26]NPY
(150 μg/rat) or vehicle immediately following the last stressor (diethyl ether) of the SPS
protocol. Animals were left undisturbed for 14 days and behavior on EPM, FST and social
interaction were assessed afterwards.
Figure 17D
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Experiment 5. The scheme of experiment is shown in Figure 17E. Rats (n = 12 rats per
group) were infused intranasally with either [D-His26]NPY (150 μg/rat) or vehicle
immediately following the last stressor (ether) of the SPS protocol. Animals were left
undisturbed for 14 days and behavior on acoustic startle response (ASR) and FST were
tested afterwards.

Figure 17E
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Result from Experiment 1 (schematic is shown in Figure 17A).
Effect of Intranasal administration of NPY Y1R agonist [D-His26]NPY on
hyperarousal and depressive-like behavior.
We examined the ability of [D-His26]NPY, in comparison to NPY, as an early
intervention to prevent the development of anxiety and depressive like behavior one week
after rats were subjected to SPS stressors (Figure 18A-D). Intranasal administration of
either [D-His26]NPY (150 μg/rat) or NPY (150 μg/rat) or vehicle were administered
immediately following the last stressor (ether) of the SPS protocol. As shown in Figure
18A, the anxiety index differed significantly among the groups (F (3, 41) = 14.54, p <
0.0001). Tukey multiple comparison test indicated that the vehicle treated group (SPS/V)
had a higher anxiety index compared to the unstressed control group (p < 0.001), the NPY
treated group (SPS/NPY) (p < 0.001) and the [D-His26]NPY treated group (SPS/D-H) (p
< 0.0001). In Figure 18B, One-way ANOVA was significant (F (3, 38) = 4.718, p < 0.01)
for time spent in the open arms (OA). Tukey multiple comparison test showed that the
SPS/D-H group spent more time (p < 0.05) in the OA than the SPS/V and the SPS/NPY
(p <0.05) groups. One-way ANOVA was also significant (F (3, 41) = 3.135, p <0.05) for
the number of entries into the OA. Tukey multiple comparisons showed that the SPS/NPY
group had more entries (p < 0.05) into the OA compared to the SPS/V group however,
neither the SPS/D-H nor unstressed control groups differed from each other or any of the
other groups (Figure 18C).
Furthermore, animals were tested for immobility on the FST as shown in Figure
18D. One-way ANOVA revealed significance (F (3, 38) = 10, p < 0.0001). Tukey multiple
comparisons showed that the SPS/V rats were immobile for a longer time (p < 0.001) than
the unstressed control group or the SPS/D-H group (p < 0.0001). The SPS/D-H group spent
less time immobile (p <0.05) compared to the SPS/NPY group. No significant differences
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were observed in the time spent immobile between the NPY treated SPS group and the
group given vehicle. In conclusion, NPY Y1R agonist [D-His26]NPY prevented SPS
elicited anxiety and depressive-like behavior.
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Figure 18

Figure 18. Effects of Y1R agonists on anxiety and depressive-like behavior. Rats were
unstressed (Control), or exposed to SPS and immediately after the last stressor (ether) rats
received intranasal infusion of 150 μg/rat of NPY (SPS/NPY) or 150 μg/rat of [DHis26]NPY (SPS/D-H). Animals were tested on the EPM and FST for effect of [DHis26]NPY after seven days on: anxiety index (A); time in OA (B); number of entries into
the OA (C); Immobility time in the FST (D).
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Result from Experiment 2 (schematic is shown in Figure 17B).

Effect of Intranasal administration of [Leu31Pro34]NPY on anxiety behavior
Intranasal infusion of either [Leu31Pro34]NPY (150 μg/rat) or NPY (150 μg/rat) or
vehicle was administered immediately following the last stressor (diethyl ether) of the SPS
protocol (Figures 19E-G). One-way ANOVA, (F(3, 32) = 4.241, p < 0.05) revealed
significance for anxiety index on the EPM. Tukey multiple comparison test showed that
the SPS/V (p <0.05) and the SPS/LeuPro (p <0.05) had a higher anxiety index compared
to the unstressed control group (Figure 19E). Results for time spent in the OA (Figure 19F)
were significant by one-way ANOVA (F(3, 31) = 9.165, p < 0.001). However, Tukey
multiple comparison tests were not significant for time spent in the OA between the
SPS/LeuPro and SPS/V groups. Both the SPS/V and SPS/LeuPro groups spent less time
(p < 0.001) in the OA compared to the unstressed control group. The SPS/NPY group also
spent less time (P < 0.05) in the OA compared to the unstressed control group. One-way
ANOVA was not significant for the number of entries into the OA (Figure 19G). Intranasal
administration of Y1R agonist [Leu31Pro34]NPY did not prevent SPS elicited anxiety. It is
also important to note that although NPY had been effective in previously published
studies, this batch of NPY was later confirmed to be of a poor quality by the manufacturer
and might explain why it wasn’t effective in the studies presented here.
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Figure 19

Figure. 19. Effects of Y1R receptor agonist on anxiety behavior. Rats were unstressed
(Control), or exposed to SPS and immediately after the last stressor (ether), 150 μg/rat of
[Leu31Pro34]NPY was administered intranasally. One week later the following measures
were tested on the EPM: anxiety index (E); time in OA (F); number of entries into the OA
(G). *p < 0.05; **p < 0.01; ***p < 0.001.
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Result from Experiment 3 (schematic is shown in Figure 17C).

Effect of Intranasal administration of NPY (3-36) on anxiety and depressive-like
behavior
Intranasal infusion of either a Y2R (NPY 3–36) agonist (150 μg/rat) or vehicle
was administered immediately following the last stressor (diethyl ether) of the SPS
protocol (Figures 20 H-K). One -way ANOVA indicated significance (F (2, 29) = 8.362,
p < 0.001) for anxiety index in Figure 10H. There was no difference in anxiety index
between the Y2R agonist treated group (SPS/Y2) and the vehicle treated group (SPS/V)
by Tukey multiple comparisons. Both the SPS/Y2 and SPS/V groups had higher anxiety
index (P < 0.05) than the unstressed control group. In Figure 20I, one-way ANOVA
revealed significance (F (2, 31) = 6.270, p < 0.01) for time spent in the OA. There was no
difference between the SPS/Y2 and SPS/V groups for time spent in the OA, both groups
spent less time (p < 0.05) in the OA compared to the unstressed control group. In Figure
20J, one-way ANOVA was significant (F(2, 26) = 15.43, p < 0.0001) for number of entries
into the OA. There was no difference between the SPS/Y2 and SPS/V groups for number
of entries into the OA by Tukey multiple comparison test. Both the SPS/V (p < 0.001) and
the SPS/Y2 (p < 0.05) had fewer number of entries into the OA compared to the unstressed
control group. In conclusion SPS elicited anxiety or depressive-like behavior was not
prevented by the intranasal administration of Y2R agonist (NPY 3–36).
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Figure 20

Figure. 20. Effects of Y2R receptor agonist on anxiety and depressive-live behavior. (NPY
3–36) on: anxiety index (H); time in OA (I); number of entries into the OA (J); immobility
time in the FST (K). Each point represents values for an individual animal. Means ± SEM
are shown. *p < 0.05; **p < 0.01; ***p < 0.001.
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Result from Experiment 4 (schematic is shown in Figure 17D).
Effect of Intranasal administration of NPY Y1R agonist [D-His26]NPY on anxiety and
social interaction
Previously we showed that the number of animals displaying severe anxiety after
SPS increased three-fold from one week to two weeks (Serova et al., 2019), indicating
progressive worsening of anxiety symptoms. Here we evaluated if [D-His26]NPY
maintained its efficacy as a potential early intervention therapy 14 days after SPS when
the anxiety phenotype is more severe (Figures 21A-C). Intranasal infusion of either NPY
(150 μg/rat), [D-His26]NPY (150 μg/rat) or vehicle was administered immediately
following the last stressor (diethyl ether) of the SPS protocol. One-way ANOVA revealed
significance (F(3, 39) = 3.592, p < 0.01) for anxiety index (Figure 21A). Tukey multiple
comparison test showed that only the [D-His26]NPY treated group (SPS/D-H) had a lower
anxiety index (p < 0.05) compared to the vehicle treated group (SPS/V). One-way
ANOVA was also significant (F (3, 33) = 3.370, p < 0.01) for time spent in the OA. The
SPS/D-H group spent more time (p < 0.05) in the OA compared to the SPS/V group (Figure
21B) by Tukey multiple comparison test. The number of entries into the OA (Figure 21C)
was also significant (F (3, 43) = 3.617, p < 0.01) by one-way ANOVA. The SPS/D-H
group had more number of entries (p < 0.05) into the OA compared to the SPS/V group.
In addition, one-way ANOVA was also significant (F (3, 34) = 4.188, p < 0.01) for
social interaction (Figure 21D). Tukey comparisons showed that [D-His26]NPY treatment
prevented the impairment in social interaction elicited by SPS in the SPS/D-H group (p <
0.01) compared to the vehicle treated group (SPS/V). In conclusion SPS elicited anxiety
and social impairment two weeks after SPS was prevented by intranasal administration of
NPY Y1R agonist [D-His26]NPY.
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Figure 21

Figure. 21. Effects of [D-His26]NPY and NPY receptor agonists on anxiety behavior. Rats
were unstressed (Control), or exposed to SPS and immediately after the last stressor (ether)
rats received intranasal infusion of 150 μg/rat of NPY (SPS/NPY) or 150 μg/rat of [DHis26]NPY (SPS/D-H) or vehicle (SPS/V). After 14 days they were tested on the EPM and
the effect of [D-His26]NPY on: anxiety index (A); time in OA (B); number of entries into
the OA (C) and social interaction (SI) (D). Each point represents values for an individual
animal. Means ± SEM are shown. *p < 0.05; **p < 0.01.
Result from Experiment 5 (schematic is shown in Figure 17E).
Effect of Intranasal administration of NPY Y1R agonist [D-His26]NPY on
hyperarousal and depressive-like behavior.
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Intranasal infusion of either [D-His26]NPY or vehicle was administered
immediately following the last stressor (diethyl ether) of the SPS protocol. Two weeks
after SPS they were tested for acoustic startle response (ASR) in Figure 22E and five days
later, they were subjected to FST (Figure 22F). One-way ANOVA revealed significance
(F(2, 43) = 3.724, p < 0.05) in the ASR. Tukey multiple comparison test showed increase
in the ASR over basal pre-SPS levels for the vehicle treated group (SPS/V) (p < 0.05) but
not the [D-His26]NPY treated animals (SPS/D-H). One way Anova was significant (F (2,
27) = 6.226, p < 0.01) in the FST two weeks after SPS. The SPS/V group spent more time
immobile than the SPS/D-H group (p < 0.01) and the unstressed control group (p < 0.05)
by Tukey multiple comparison test.
These results show that intranasal administration of Y1R agonist [D-His26]NPY can
protect against depressive/despair behavior and impaired social interaction in a rodent
PTSD model two weeks after symptoms are more severe.
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Figure 22

Figure. 22. Effects of [D-His26]NPY receptor agonist on acoustic startle response (ASR)
(E); immobility time in the FST (F). Each point represents values for an individual animal.
Means ± SEM are shown. *p < 0.05; **p < 0.01.
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In summary these results suggest that Y1R is a key mediator of NPY's protective effects
on anxiety and depressive-like symptoms emanating from exposure to severe stress.
Activation of the Y1 receptor protected against the development of anxiety, impairments
in social interaction and depressive/despair-like behaviors. [D-His26]NPY was especially
effective compared to [Leu31Pro34]NPY. In the FST, [D-His26]NPY was more effective
than NPY in decreasing immobility time in the FST.
Gene expression changes of CRH and NPY systems in the LC and Mediobasal
hypothalamus two weeks after SPS
The HPA axis is a classic neuroendocrine loop. Neurosecretory neurons located
in the medial parvocellular paraventricular nucleus (PVN) of the hypothalamus initiates
the secretion of glucocorticoids (Antoni, 1986; Whitnall, 1993). Glutamatergic and
noradrenergic transmissions innervate the PVN stimulating CRH release to activate the
HPA axis. Enhanced innervation is associated with chronic stress
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. PVN neurons are

divided into parvocellular and magnocellular divisions while CRH neurons in the PVN are
mostly the parvocellular division (Aguilera, 1998: Sawchenko et al., 1985). GRs are also
expressed by most neurons expressing CRH in the rat PVN (Agnati et. al., 1985).
Inhibitory effect of GRs on CRH following repeated stress show a correlation between the
decrease in GR mRNA levels in the PVN and increased CRH levels (makino et al., 1995).
In addition, the LC is also an important target for the PVN CRF projections. PVN neurons
projecting to the LC are positive for CRF immnunorecativity (Ryes et al., 2005) and have
their synapses on both catecholaminergic and non-catecholaminergic cells in the LC.
Ascending LC norepinephrine containing projections innervate multiple sites in the brain,
including the PVN, amygdala, hippocampus and the cerebral cortex (Hwang et al., 1998).
Stressful events activate the LC leading to an increase of norepinephrine (NE) release in
these brain regions, making it possible that the LC can influence different brain functions
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and behaviors that include vigilance, attention, arousal memory acquisition, locomotor
control and response to stress (Aston-Jones et al., 1996; Berridge and Waterhouse, 2003;
Morilak et al., 2005; Sara, 2009; Valentino and Van Bockstaele, 2008).
Therefore, we speculated that PTSD core symptoms observed in the SPS animals
could result from the progressive dysregulation of some of these neuronal networks. We
evaluated molecular changes in both LC and mediobasal hypothalamus following SPS
because these two brain regions have been implicated in mediating responses to stress
arising from the dysregulation of the HPA axis. It was previously shown that stress
increased tonic LC-NE activity an event necessary and sufficient for stress-induced
anxiety and aversion (McCall et al., 2015). The PVN located in the medial basal
hypothalamus is required for activation of the HPA axis and is implicated in the
development of pathologies arising from the dysregulation of the HPA. Furthermore, the
LC is highly responsive to stressful stimuli that activate the HPA axis. Therefore,
investigating molecular changes in these brain regions could shed some light on genes that
respond to chronic stress in the SPS animal model.
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Changes in the CRH and NPY system in the LC

Figure 23. Changes in gene expression in locus coeruleus at two weeks after exposure to
SPS stressors. A. CRH receptor 1 (CRHR1) mRNA levels. B. NPY mRNA. C. Y2R
mRNA. D. Y1R mRNA. E. Y5R mRNA
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We examined changes in the gene expression of the CRH and NPY systems two weeks
after exposure to SPS stressors in two separate experiments by t-tests. CRHR1 mRNA
was elevated in the SPS animals compared to the unstressed controls (p < 0.001, Figure
23A) with wide variation among the animals. The SPS group had lower NPY mRNA
levels compared to the unstressed controls (p < 0.05, Figure 23B). Similarly, there was
a reduction in the Y2R mRNA levels in the SPS group two weeks after SPS compared
to the unstressed controls (p < 0.01, Figure 23C). By contrast, no changes were
observed in levels of Y1R and Y5R mRNAs two weeks after SPS stressors (Figures
23D and E).
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Changes in the CRH and NPY system in the mediobasal hypothalamus

Figure 24. Changes in gene expression of CRH, GR and FKBP5 in the mediobasal
hypothalamus after exposure to SPS stressors. A. CRH, B. GR, and C. FKPB5 two weeks
after SPS. D. Y1R mRNA. E. Y2R mRNA and F. Y5R mRNA levels at one and two weeks
after the SPS. Data points represent an individual rat with mean (horizontal line). **p <
0.01, ***p <0.001.
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In the Medio basal hypothalamus CRH mRNA levels were elevated over the unstressed
controls (Figure 24A, p < 0.001). The mRNA levels for GR (Figure 24B) and FKBP5
(Figure 24C) were decreased (p < 0.01) compared to the unstressed controls. The effect of
SPS on levels of gene expression of NPY receptors in the mediobasal hypothalamus were
evaluated one and two weeks after SPS. Y1R mRNA levels were unchanged (Figure 24D)
however, changes in Y2R (Figure 24E) and Y5R (Figure 24F) mRNAs were observed one
week after the traumatic stress of SPS. After two weeks, Tukey multiple comparison test
revealed that only the Y5R was significantly (p < 0.01) reduced in the SPS group compared
to the unstressed control (Figure 24F).
Overall, these results show pronounced changes in the CRH and NPY gene
expression system in both the LC and mediobasal hypothalamus 2 weeks following a
single exposure to SPS stressor (summarized in Tables 3-5).
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Table 3. Changes in mRNA expression in the LC
2 weeks post SPS
Increase

Decrease

No Change

CRHR1

NPY, Y2R

Y1R, Y5R

Table 4. Changes in mRNA expression in mediobasal hypothalamus
I week post SPS
Increase

No Change

Y2R, Y5R

Y1R

Table 5. Changes in mRNA expression in mediobasal hypothalamus
2 weeks post SPS

Increased

Decrease

No Change

CRH

GR, FKBP5, Y5R

Y1R, Y5R
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Table 6. Representative qPCR program
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Table 7
Representative Amplification Raw Data

Rn is the fluorescence of the reporter dye divided by the fluorescence of a passive reference
dye.

Table 8
Representative Melting Point Raw Data

Divergent Expression of the Norepinephrine Transporter (NET) in the LC following
SPS
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2 weeks post SPS
A.

B.

Figure 25. Changes in the Norepinephrine Transporters (NET) expression in the LC two
weeks after exposure to SPS stressors. A. NET mRNA. B. NET mRNA divided into low
and high groups. Low and high NET mRNA expression levels were based on mRNA
expression level below the mean and mRNA expression level above the mean,
respectively. Each point represents values for an individual animal. **p < 0.01. For
normality and log normality test the controls had a normal distribution while the SPS did
not have a normal distribution. For both the Anderson-Darling and Kolmogorov-Smirnov
(K-S) test, the control group passed normality test while the SPS group failed normality
test. The mean was used to divide the SPS animals into two subgroups to visualize the
large variety within the group. However, it doesn’t give the result a different interpretation.
The results show that there is variability between animals that received SPS compared to
the unstressed controls.
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4 weeks post SPS
A.

B.

Figure 26. Changes in the Norepinephrine Transporters (NET) expression in the LC four
weeks after exposure to SPS stressors. A. NET mRNA. B. NET mRNA divided into low
and high groups. Low and high NET mRNA expression levels were based on mRNA
expression level below the mean and mRNA expression level above the mean respectively.
Each point represents values for an individual animal. ****p < 0.0001. For normality and
log normality test the controls had a normal distribution while the SPS did not have a
normal distribution. For both the Anderson-Darling and Kolmogorov-Smirnov (K-S) test,
the control group passed normality test while the SPS group failed normality test. The
mean was used to divide the SPS animals into two subgroups to visualize the large variety
within the group. However, it doesn’t give the result a different interpretation.
Two weeks after SPS, animals exposed to SPS stressors had divergent NET mRNA
expression. Based on the variability in the SPS exposed group, we divided the SPS group
to two subgroups, above and below the mean. One-way Anova revealed significance (F
(2, 19) = 57.78; P < 0.0001) and Tukey multiple comparison tests showed significance (p
< 0.0001) between low NET mRNA and high NET mRNA expressing animals. There was
no significant difference between animals with low NET mRNA expression compared to
the unstressed controls (Figure 25). In a different cohort of animals, divergent NET mRNA
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expression was also observed four weeks after SPS (Figure 26), one-way ANOVA
revealed significance (F (2, 22) = 23.66, P<0.0001). Tukey multiple comparison tests
showed significance (p < 0.0001) between low NET mRNA and high NET mRNA
expressing animals. There was no significant difference between animals with low NET
mRNA expression compared to the unstressed controls.
These result indicate that animals in the SPS group had a divergent NET mRNA
response to SPS and putting these animals into two subgroups is another way to visualize
the divergent NET mRNA expression within the SPS group. The divergence NET mRNA
expression in the LC has not been consistently observed in other mRNA expressions that
we analyzed in the LC.
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Effects of NPY on NET mRNA Expression in the Locus Coeruleus two weeks post
SPS.
Early Intervention with NPY

Relative NET mRNA expression

15

10

5

0
Control

SPS/V

SPS/NPY

Figure 27. Effect of intranasal NPY on NET mRNA expression levels in the locus
coeruleus two weeks after SPS.
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In this cohort of animals, the divergence of NET mRNA expression in the SPS/V
group is less compared to the divergence we observed for the cohorts in Figures 25 and
26. This is not surprising because they are of different cohorts and are all out breed. In
addition to the previous experimental groups, here we had two groups of animals exposed
to SPS stressors. One group received vehicle (SPS/V) and the second group was given
intranasal NPY (SPS/NPY). NET mRNA expression of the SPS/NPY group exhibited
responses similar to those of the unstressed controls, it was not significantly different from
the SPS/V group. NPY tended to reduce the increase in NET mRNA expression in the
SPS/NPY group two weeks after SPS.
In summary, these results show that two weeks after exposure to SPS stressors,
the NET mRNA expression of about 60% of the animals were similar to the control group
while approximately 40% of animals had a higher NET mRNA expression. In a different
cohort, four weeks after SPS, about 50% of the animals had NET mRNAs that were similar
to the control group and the other 50% of the animals had a higher NET mRNA expression.
Furthermore, early intervention with intranasal NPY tended to lower the increase in NET
expression in a different cohort of animals two weeks after SPS.
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The effects of SPS and ASR on Gene expression in the Medio basal Hypothalamus
and
LC
Since hyperarousal is associated with activation of the NE/LC system 38, 154 and is
elevated in PTSD

38

as well as by SPS

79, 81

we examined the effects of SPS triggered

changes and acoustic startle response (ASR) on CRH, NPY and NET mRNA levels in both
the mediobasal hypothalamus and the LC of the SPS animal model. ASR is LC specific
because hyperarousal originates primarily in the LC which would enable the study of NET
mRNA expression following ASR.
Schematic of experimental groups

93

Figure 28. Mean amplitudes of startle. (A) ASR of A‐A group (not exposed to SPS) at 100
and 115 db. (B) A‐S‐A group (exposed to SPS) at 100 and 115 db. For ASR1, data from
A‐A and A‐S‐A groups were combined. (C) ASR2 measured at 115 db for A‐A and A‐S‐
A groups, n = 8 for the A‐A group and n = 11 animals for the A‐S‐A group. Means ±
S.E.M. are shown. Each point represents values for an individual animal. *P < 0.05,
**

P < 0.01, ***P < 0.001, ****P < 0.0001.
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Acoustic Startle Response
ASR was measured at both 100 and 115 decibels. ANOVA analysis showed
differences in ASR at 100 and 115 dB (F (3,38) = 14.7, P < 0.0001). Tukey comparisons
of the means revealed that the startle response was much higher at 115 dB in both the A‐
A and A‐S‐A groups. The ASR of animals not exposed to SPS (A‐A) was similar in both
the first (basal ASR1) and the second (ASR2) test 15 days later at both 100 and 115 dB
(Figure 28A). There were significant differences in ASR in the A‐S‐A group (F (3, 40) =
43.4, P < 0.0001). The startle response in the second test (ASR2) was significantly higher
than for ASR1 at 115 dB (Figure 28B). The response to ASR2 at 115 dB was also greater
in the stressed (A‐S‐A) compared with the unstressed (A‐A) group (Figure 28C).
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mRNA changes in the Mediobasal hypothalamus

Figure 29. Changes in gene expression in the mediobasal hypothalamus. Relative mean ±
SEM mRNA levels for CRH (A), GR (B), FKBP5 (C), Y1R (D), Y2R (E), and Y5R (F)
are shown. Each point represents values for an individual animal. *P < 0.05, **P < 0.01.
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The mRNA levels for CRH, GR, FK506 binding protein (FKBP5), and Y1R, Y2R, and
Y5R receptor subtypes were measured in the mediobasal hypothalamus (Figure 29) to
assess the possible influence of AS on PVN regulation with or without SPS exposure. CRH
gene expression was altered (F (3,32) = 6.19, P < 0.01). CRH mRNA levels were higher
than unstressed controls in all the groups, including the A-A group not exposed to SPS
(Figure 29A). There were significant differences between the groups in GR and FKBP5
mRNA levels (F (3, 34) = 5.13, P < 0.005 for GR and F (3, 41) = 4.390, P < 0.01 for
FKPB5). The mRNA levels for GR and FKPB5 in the A-A group were similar to controls.
SPS reduced GR and FKBP5 mRNA expression (Figures 29B and C). Tukey comparison
for both genes shows that the SPS group without AS is lower than in controls (P < 0.01, P
< 0.05, respectively). However, there was no effect of SPS on GR or FKBP5 mRNAs in
the group with basal ASR measurement (A-A vs A-S-A). One-way ANOVA analysis
showed significance in gene expression for Y1R and Y5R (F (3, 32) = 2.56, P < 0.05 and
F (3, 41) = 4.33, P < 0.01, respectively) but not Y2R (Figure 29D–F). Tukey comparisons
showed that Y1R mRNA was elevated over the unstressed control group in the A-A group
(P < 0.05) and Y5R mRNA levels reduced in the SPS group not exposed to ASR compared
with the unstressed controls (P < 0.05).
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mRNA changes in the Locus coeruleus
Figure 30

Figure 30. Changes in gene expression in the locus coeruleus. Relative mean ± SEM
mRNA levels for: CRHR1 (A), pre-pro NPY (NPY) (B), Y1R (C), Y2R (D), and Y5R (E)
are shown. Each point represents values for an individual animal. *P < 0.05, ***P < 0.001.
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There were significant differences in CRHR1 mRNA levels (F (3, 41) = 14, P < 0.001).
CRHR1 was elevated (P < 0.001) only in the SPS group not exposed to ASR (Fig. 30A).
One-way ANOVA analysis reveals differences in the expression of prepro‐NPY mRNA
levels (F (3, 30) = 6.5, P < 0.01). Tukey comparison revealed that the SPS and A-S-A were
significantly lower than the mean of the A-A group (P < 0.001, P < 0.05, respectively)
(Figure 30B). The mRNA levels were determined for the NPY receptor subtypes (Figures
30C–E). There were no differences in Y1R, but Y2R and Y5R were changed (F (3, 30) =
7.952, P < 0.001) and (F (3, 38) = 4.1, P < 0.01), respectively. Y2R and Y5R mRNAs
were elevated in the A-A group over the unstressed controls (P < 0.05). The exposure to
SPS (A‐S‐A group) reduced the mRNA levels for both Y2R and Y5R (P < 0.05).
These results revealed that acoustic startle (AS) alone triggered some changes
through elevation of Y2R and Y5R mRNAs in the LC and CRH mRNA in the mediobasal
hypothalamus was also elevated by either SPS, AS alone or both AS and SPS to similar
levels. Current studies in the laboratory are focused on studying the effects of forced swim
tests (FST) and elevated plus maze (EPM) in conjunction with changes in gene expression
in the both the LC and mediobasal hypothalamus.
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Divergent Expression of the Norepinephrine Transporter (NET) in the LC and
relationship with Acoustic Startle

Figure 31. Acoustic startle response and NET gene expression in the locus coeruleus of
the same cohort of animals. (A) ASR (B) NET mRNA levels in all groups (C) A-A group,
NET mRNA is divided into low and high expression (D) A-S-A group, NET mRNA is
divided into low and high expression. Low and high NET mRNA expression levels were
based on mRNA expression level below the mean and mRNA expression level above the
mean respectively. Each point represents values for an individual animal. *P < 0.05,
**

P < 0.001.
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Correlation of the NET mRNA and ASR in the LC
Figure 32

Figure 32. NET mRNA expression and ASR correlation. (A) High NET mRNA group Vs
ASR (B) Low NET mRNA group vs ASR (C) NET mRNA of both groups combined and
ASR. Low and high NET mRNA expression levels were based on mRNA expression level
below the mean and mRNA expression level above the mean respectively. Each data point
represents values for an individual animal.
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ASR was higher in the A-S-A group. There was a divergence in the NET mRNA
expression of animals that were exposed to acoustic startle alone (A-A) and both acoustic
startle and SPS (A-S-A) in Figure 32A-D. t- test showed significance (p< 0.01) in A-A
low vs high and in A-S-A low vs high (C & D). In addition, we observed a negative
correlation of 0.9 and p < 0.01 between acoustic startle response and NET mRNA
expression in the low subgroup of the A-S-A group (Fig 32A). There was not a strong
correlation in the high subgroup of the A-S-A high group (Figure 32B). A correlation of
0.56 was observed when both subgroups were combined (Figure 32C). There was no
relationship between ASR and NET mRNA in the A-A group (not shown). In conclusion,
the SPS elicited changes in NET mRNA levels in the LC displayed a U-shaped relationship
with the changes in acoustic startle. In addition, there was a negative correlation between
changes in NET mRNA in the LC and ASR in the subgroup of animals that had lower NET
mRNA expression level.
5.4.2 Norepinephrine transporter methylation analysis in the LC
Following the results on the correlation between changes in NET mRNA
expression in the LC and hyperarousal in the A-S-A low group and coupled with the
divergent NET mRNA response to SPS and acoustic startle we evaluated the methylation
status of the NET promoter in the SPS treated animals compared to the unstressed controls.
In addition, a study showed differential methylation at the NET promoter in ADHD
patients. Two weeks after SPS we isolated both the left and right LCs and performed NET
RT-PCRs using the right side of the LC. Based on the NET mRNA expression level result,
in the SPS/V group we identified representative animals with low NET mRNA expression
levels and those with high NET mRNA expression levels. Methylation analysis of the
NET promoter using the left LC corresponding to the representative animals and the
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unstressed control animals was performed. One-way ANOVA revealed significance (F (2,
9) = 4.381, P < 0.05) between groups.
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Representative animals selected for promoter methylation

Relative NET mRNA expression

Figure 33
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Figure 33. NET mRNA expression. Each data point represents values for an individual
animal.
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Two CpG regions in the NET promoter were studied slc6a2-1 and slc6a2-2

Figure 34. NET promoter methylation analysis. CpG region is shown (the red curve is the
GC content, the green curve is the observed/expected (O/E) value and the yellow box
represents the CpG Island). The ratio of observed to expected CpG is calculated as Obs
/Exp CpG = Number of CpG * N / (Number of C * Number of G) where N = length of
sequence. CpG locus sequenced relative to promoter start site are region1(slc6a2-1) -1199
to -947 and region 2 (slc6a2-2) -339 to -614.
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NET Promoter Methylation

Figure 35. Region 1 (slc6a2-1) CpG methylation. (A) Control vs High NET (B) Control
vs Low NET (C) High Net vs Low NET. Region 2 (slc6a2-2) CpG methylation. (D)
Control vs High NET (E) Control vs Low NET (F) High Net vs Low NET. Each data point
represents methylation sites. * p < 0.05

106

We found that representative SPS animals with low NET mRNA expression had increased
methylation in CpG sites in region 2 of the promoter compared to either representative
SPS animals with higher NET mRNA expression (p < 0.05) or the unstressed control
animals (p < 0.05). There were no differences in methylation of CpG sites in region
1(Slc6a2-1).
Next, we wanted to evaluate NET protein expression in the SPS animal model.
Chronic social stress was shown to increase NET mRNA and protein levels in the rodent
LC and the projection regions of the hippocampus, frontal cortex and amygdala which
could lead to reduced NE at their synapses 155.It has been suggested that the induction of
NET is mediated by activation of the HPA axis. Chronic treatment with corticosterone for
21 days appeared to mimic this effect and increased NET mRNA and protein in the LC,
and NET protein levels also in the hippocampus, frontal cortex and amygdala 156. NE from
the LC is involved in the encoding, consolidation, retrieval and reversal of hippocampal
based memory 157. NE was shown to regulate transcriptional control of long-term plasticity
to gate the endurance of memory storage, the LC/NE system is key in orchestrating
longevity of hippocampal-dependent memory 157.
We therefore evaluated the relative levels of NET protein in the LC and the
hippocampus, a key target area for many of the effects of stress.

107

Reduced NET protein expression in the LC after SPS.

Figure 36. NET protein expression (A) Two weeks after SPS in the LC (B) Four weeks
after SPS in the hippocampus (C) Two weeks after SPS in the medial prefrontal cortex
(mPFC). Each point represents values for an individual animal. *P < 0.05, **P < 0.01.
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NET protein expression was evaluated in the LC of animals that received only
acoustic startle (AA) and animals that received both acoustic startle and SPS stressors and
left undisturbed for two weeks. NET protein expression of animals that received both
acoustic startle and SPS were lower (p < 0.01) than the animals that received only acoustic
startle. In the both the hippocampus and mPFC, efferent terminals for projections from the
LC, NET protein was reduced compared to the group not exposed to SPS. However, in the
hippocampus of the SPS group, about 30% of the animals had NET protein expression
level below the mean while 70% of the animals had NET protein expression levels above
the mean and similar to the unstressed controls. A t-test revealed significance (p < 0.01)
between the unstressed controls and the SPS group.
Based on this results we speculate that reduced NET protein in the LC could
mediate exaggerated noradrenergic activation following a traumatic event and that reduced
NET in the hippocampus could enhance memory consolidation of the trauma resulting in
an increased chance of re-experiencing the traumatic event when a reminder presents.
More studies are ongoing to further ascertain if these speculations are indeed correct.
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Discussions
Development and progression of anxiety symptoms and the effects of Intranasal NPY
treatment
Our studies show that anxiety symptoms worsen with time and would require
doubling the dose of intranasal NPY for effective treatment (Figure 12). Intranasal infusion
with 300 µg/rat reverses the SPS-elicited depressive like behavior in the FST. In our
studies, the FST represented an element of re-experiencing because forced swim in the
same cylinders was one of the SPS stressors. The implication is that re-experiencing could
lead to potentially developing coping mechanisms to the forced swim test confounding the
effects from SPS. Enhanced immobility on the FST has been interpreted as representing
depressive/despair behavior or more accurately, shift from active to passive coping
behavior 158. FST has also been used to show the ability of ketamine to alleviate symptoms
of depression 159. It is also important to note that there have been considerations on whether
the forced-swim test is a good model for depression in people. Furthermore, tests that
accurately measure specific symptoms of depression, such as lack of interest in a task that
used to be enjoyable could be more predictive of depressive-like symptoms.
NPY antagonizes the responses to stress-elicited elevation in CRH 160, 161, therefore
activation of Gi by NPY would inhibit the CRH triggered elevation of cAMP by Gs. The
Sabban laboratory has shown that early intervention with NPY delivered to the rat brain
by intranasal infusion reduces the SPS-triggered activation of the HPA axis, elevation of
plasma corticosterone or ACTH, and induction of GR in the hippocampus 78, 81. 300µg/rat
of NPY reversed hyperarousal (Figure 15). The reversal in hyperarousal was sustained and
evident a week after administration of the intranasal NPY (Figure 16). It is speculated that
PTSD could be

associated with progressive neuronal sensitization
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, however the

neuronal mechanisms is unclear. In neuronal sensitization PTSD patients could appear to
be unusually responsive to stress in contrast to as being less responsive to stress as seen
by models of glucocorticoid resistance. It is speculated that this sensitivity would lead to
change in excitability of neurons but causes and effects of neuronal sensitization is still
unclear. NPY could be acting to depress the post-synaptic potential of LC neurons, via
pre-synaptic Y2 receptors on the soma of the noradrenergic neurons 63, 163.
The Sabban laboratory showed previously that intranasal NPY also inhibits SPSelicited activation of the locus coeruleus-noradrenergic system and induction of CRH in
the central nucleus of the amygdala 96. These results reinforce the idea that the severity of
PTSD symptoms will determine how treatment is given as a higher dose of NPY may be
required at longer times after SPS. These findings reinforce the idea that therapeutic
treatment with NPY, or other medications to reverse or improve PTSD symptoms, to be
administered according to the degree of the severity of the disorder and the sooner the
better.
NPY Receptors Subtypes
The NPY Y1R subtype is sufficient in mediating the effects of NPY or [D-His26]
NPY to prevent the development of SPS elicited anxiety, social impairment and
depressive-like behavior. We showed that intranasal administration of Y1R agonist [DHis26]NPY can protect against the development of anxiety, depressive/despair behavior
and impaired social interaction in the SPS rodent PTSD model
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. However, the Y1R

preferring agonist [Leu31Pro34]NPY was not effective for anxiety, although it inhibited the
development of depressive-like behavior on the FST as well as sucrose preference 165. By
contrast, the Y2R agonist was not effective neither for anxiety nor for depressive-behavior.
NPY displays 4-25-fold higher affinity for the Y2 receptor than for the Y1 receptor. The
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affinity of [Leu31,Pro34]NPY is 7-60-fold higher for the Y1 receptor when compared with
the Y2 subtype 118.
Other factors that can influence the activity of agonists include binding affinities
to receptors, concentration and stability. Our results show that activation of the Y1R by
[D-His26]NPY prevented the development of the symptoms of anxiety, social impairment
and depressive-like behavior. Additional studies using specific receptor antagonist would
further confirm that the effects of the agonist was mediated by the receptor.
The results on the effectiveness of Y1R agonist [D-His26]NPY are consistent with
earlier studies which have shown that anxiolytic-like effects of NPY are mediated via Y1
receptors while activation of Y2 receptors are anxiogenic. For example, Y1R antisense
treatment of animals resulted in anxiogenic-like behavior on the EPM
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. The Y1R

preferring agonists [Leu31Pro34]NPY and [D-His26]NPY were shown previously to have
an anxiolytic-like effect in animals in the plus maze 74, 119, 166. However, these results were
in unstressed animals and not after exposure to traumatic stress. Here, single intranasal
infusion of [D-His26]NPY right after the traumatic stress was effective even two weeks
afterwards, a time when SPS triggered anxiety is more severe 164.
In Y1R−/− mice, anxiety related parameters, such as distance travelled in the
central area of an open field or open arm entry on the EPM were increased compared to
the wild type. Interestingly, the anxiety-like phenotype in the Y1R mutant mice was
dependent on several factors including circadian rhythm and prior stress exposure 167. The
icv administration of NPY to Y1R mutant mice did not produce anxiolytic-like effect in
the EPM observed in WT mice, suggesting that the Y1R was needed for the anxiolytic
effects
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. Previously, we showed that Y1R preferring agonist [Leu31Pro34]NPY was

effective in preventing development of depressive-like symptoms following the exposure
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to SPS 165. However unlike [D-His26]NPY, it was not effective to thwart development of
anxiety behavior. This could be due to [Leu31Pro34]NPY also activating Y5R
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. [D-

His26]NPY has about 18 fold higher affinity for human Y1R than for Y5R and is 375 times
more selective for rat Y1R than for Y5R to inhibit forskolin stimulated cAMP production
103

.

Table 9. NPY Receptor Affinity
Receptors
NPY (nM)
[D-His26]NPY
(nM)

Y1
0.28±0.06
2.0±0.3

Y2
1.2±03
29.0±4.7

Y4
ND
20.1±1.9

Y5
1.5±0.1
34.6±3.8

Adapted from Mullins et al., 2001103 .
Alternatively, [D-His26]NPY may be more stable, due to the presence of its Damino acid 170. This could make it more efficient in reaching different areas of the brain.
The molecular mechanism of attenuation of traumatic stress sequelae by early intervention
with intranasal NPY or Y1R agonists remains to be clarified.
Interestingly, we found that the [D-His26]NPY was more effective than NPY to
prevent the development of immobility on the FST. This could be due to the ubiquitous
binding of NPY with high affinity and less selectivity for receptor subtypes or perhaps due
to the greater stability of [D-His26]NPY. NPY can act as a resilience factor by impairing
associative implicit memory after stressful and aversive events, as evident in models of
fear conditioning, presumably via Y1 receptors in the amygdala and prefrontal cortex 171.
Y1R deficient mice have significantly elevated immobility on FST compared to wild type
animals suggesting that Y1 receptor agonist might have anti-depressive effects. However,
they also displayed anti-depressive related response to fluoxetine, an anti-depressant 168.
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In addition Y1 receptor stimulation attenuates the somatic signs associated with
nicotine withdrawal making NPY or Y1 receptor agonists, [D-His26]NPY potentially an
effective treatment for symptoms associated with the discontinuation of tobacco smoking
171

.

[D-His26]NPY prevented development of the impaired social interaction (Figure 21)
triggered by SPS. Its effects on hyperarousal need to be investigated further. There were
large variations in the ASR of the SPS/V group (Figure 22), such that it is difficult to
conclude whether or not [D-His26]NPY was effective.
By contrast to Y1R agonist, the Y2R agonist NPY (3-36) did not prevent the
anxiety or depressive-like behavior observed one week after SPS (Figure 20). In neurons
that contain NPY, the Y2 receptor is mostly located presynaptically and negatively
regulates NPY release

65, 172, 173

. The icv injection of Y2R-preferring agonist resulted in

anxiogenic effect in the plus maze and social interaction tests 115, 116, 166. Furthermore, the
Y2 receptor knockout mice show less anxiety and more anti-depressive related behaviors
112, 174, 175

. However, results from the use of Y2R agonists have been diverse and depended

on task and region

76, 176

. In contrast to our studies, the Y2 receptor preferring agonist

NPY(3–36) did not attenuate the SPS elicited anxiety, as rats treated with the NPY(3–36)
had similar anxiety levels as the vehicle treated group. In a previous study, a selective Y2R
agonist was anxiogenic in the social interaction test when injected into the amygdala
116

115,

. While we have not examined the Y2R agonists for social interaction following SPS, in

this study we found that [D-His26]NPY blocked development of anxiety-like responses in
the social interaction test (Figure 21) two weeks after SPS. Several studies have shown
that NPY in the basolateral amygdala plays an important role in reducing anxiety-like
behaviors, impairments in social interaction test and in fear responses 113, 115, 116, 177. Based
on the findings of other research groups and our studies, Y1R is possibly a key mediator
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of NPY's protective effects on anxiety and depressive-like symptoms emanating from
exposure to severe stress. Activation of the Y1R is sufficient to protect against the
development of anxiety, impairments in social interaction and depressive/despair-like
behaviors. [D-His26]NPY was especially effective compared to [Leu31Pro34]NPY. It was
even superior to NPY as an early intervention therapy to prevent the development of
depressive-like symptoms and may have great therapeutic potential.
Furthermore, it is worthy to note that although it iswhether known that Y1, Y2
or Y5 receptor agonists can act as biased ligands, a more recent study showed that
substitution of position Q34 of neuropeptide Y to glycine (G34-NPY) demonstrated
selectivity over all YR subtypes 178 and displayed a significant bias towards activation of
the Gi/o pathway and enhanced signaling over recruitment of arrestin-3 (Figure 37). Gprotein coupled receptor (GPCR) signaling is a ligand-receptor-transducer complex that
leads to a conformational state of the receptor. When stabilized by a selective biased ligand
it promotes interaction with specific transducers such as G-protein or β-arrestin to evoke
selective non canonical cellular signaling responses 179. The advantage is that it provides
opportunity to direct a Y1R agonist for more therapeutic potentials while minimizing off
target or side effects.
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Figure 37 - Biased ligand G ptrotein signaling

Adapted from Kaiser et al., 2020 178.
Figure 37. Proposed mechanism of Y1R biased ligand G protein signaling
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Gene expression changes in the LC and mediobasal hypothalamus after SPS
Changes in the NPY and CRH mRNA expression were observed in the LC and
mediobasal hypothalamus two weeks after SPS. Gene expression of CRHR1, the receptor
subtype expressed in the LC, was previously shown to be elevated in a subset of animals
one week after SPS

96

. Here, significant changes in CRHR1 persist and are especially

robust after 2 weeks.

Figure 38. Summary of gene expression in the LC and mediobasal hypothalamus
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There is a progressive dysbalance between the CRH and NPY systems in the LC
as increased gene expression of CRHR1 (Figure 23) is accompanied by a sustained
reduction of Y2R and NPY (Figure 23). Increase CRHR1 gene expression can enhance the
ability of the LC to respond to the “pro-stress” CRH relative to the buffering NPY input
in the weeks following SPS stressors. CRH afferents, arising primarily from the amygdala,
PVN, Barrington’s nucleus and nucleus paragigantocellularis project to the LC and
provide a neuroanatomical pathway for an interaction between CRH and LC/NE neurons
180

. CRH drives the high tonic state of LC neuronal activity while simultaneously

decreasing phasic firing events in the LC 181, 182. CRH projections from the central nucleus
of the amygdala to LC promotes an anxiogenic response, which is mediated by CRHR1
receptors 33.
Microinjections of NPY as well as agonist for Y2R, but not Y1R, into the vicinity
of the LC, had anxiolytic effects on the EPM 76. Exogenous NPY, possibly via Y2R, could
depress the post-synaptic potential of LC neurons and potentiate the inhibitory effects of
NE on the cell somata, thus reducing the firing of LC neurons 163. SPS-triggered changes
were observed in LC in several members of the NPY system, including NPY and Y2R.
NPY is co-expressed with NE in 20–40% of LC neurons and projects to many brain regions
including the hippocampus and cerebral cortex

183, 184

. Y2R is primarily a presynaptic

receptor. It is involved in attenuating release of NE, as well as GABA. Sustained reduction
of Y2R expression would be associated with down regulation of presynaptic inhibition,
and over-activation of noradrenergic systems 82. However, this is contrary to the study that
showed less anxiety and more anti-depressive related behaviors in the Y2R knock out
mice.
In contrast to the consistent elevation of the CRH gene expression a flip in the
regulation of GR and FKBP5 gene expression between one and two weeks post-SPS
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stressors was observed 164. The mRNAs for GR and FKBP5 were increased over levels in
unstressed rats in the early stage seven days after the SPS 78 they were down regulated by
2 weeks. Ligand activated GR plays a crucial role in direct glucocorticoid feedback by
repressing CRH biosynthesis and thus enabling appropriate termination of the stress
response. GR sensitivity to corticosterone, at least partially, depends on FKBP5.
Functional variations in the FKBP5 gene are associated with biologically distinct subtypes
of PTSD and predicting the severity of its onset 26. When FKPB5 is bound to the GR via
Hsp90, the receptor has lower affinity for its ligand and remains in the cytoplasm instead
of translocation to the nucleus. At 2 weeks after SPS, the, persistent activation of CRH
transcription may be due to decreased levels of FKBP5 and, as a consequence, more
translocation into the nucleus. Conversely, the reduced levels of FKBP5 mRNA may result
from the reduction in GR gene expression, since the transcription of the Fkbp5 gene is
regulated by GR. FKBP5 is a co-chaperone of hsp90 that regulates glucocorticoid receptor
(GR) sensitivity. When FKBP5 is bound to the receptor complex, cortisol binds with lower
affinity and nuclear translocation of the receptor is less efficient. Cortisol binding allows
efficient nuclear translocation of GR. FKBP5 mRNA and protein expression are induced
by GR activation via intronic hormone response elements providing an ultra-short
feedback loop for GR-sensitivity 24. The PVN receives NPY mainly from the hypothalamic
arcuate nucleus which innervates numerous PVN-CRH neurons 185 acting most probably
via Y1R, Y2R and Y5R, Gi/Go coupled receptors

186

. NPY has a bimodal concentration-

dependent effect on neuronal discharge of PVN neurons with excitatory responses at low
concentrations, which may be mediated by Y1R and inhibitory responses at high
concentrations mediated most probably by Y5R 187. In unstressed rats, icv infusion of NPY
into the brain increased CRH mRNA levels, predominantly via Y1R

188

. However, in

stressed animals NPY promotes adequate termination of stress therefore reducing exposure
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of the body to high levels of stress hormones and subsequently protects against harmful
stress-related impairments 81, 85.
We found that SPS triggered changes in gene expression for several NPY
receptors subtypes in the mediobasal hypothalamus. Despite its effects on anxiety, we did
not detect changes in Y1R mRNA expression in the mediobasal hypothalamus at any of
the time points. However, Y5R mRNA was significantly altered after one and two weeks
(Figure 24). Since the functions of Y1R and Y5R on anxiety behavior are similar

119

and

higher levels of both receptors are associated with reduced anxiety 189, we speculate that
decreased Y5R at two weeks might contribute to severity of anxiety. However, the ratio
Y1R/Y5R might also play an important role as conditional deletion of Y1R from Y5R
expressing neurons caused an increase in anxiety behavior 190. Interestingly, like GR and
FKBP5, there was also a flip in the gene expression of Y5R which was up-regulated one
week after SPS and down regulated after two weeks (Figure 24). The Y2 receptor subtype
was markedly increased, but only at one week following the SPS (Figure 24). Potential
Y2R signaling may be anxiogenic, since as an autoreceptor its activation leads to a
reduction in NPY release via a negative feedback loop 191.
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Gene expression changes in the LC and mediobasal hypothalamus after acoustic
startle and SPS
Analysis of changes in gene expression in the LC revealed that acoustic startle (AS)
by itself was sufficient to trigger some changes, specifically elevation of Y2R and Y5R
mRNAs (Figures). In the mediobasal hypothalamus, CRH mRNA was also elevated by
either SPS or AS alone to similar levels (Figure 29). Exposure to AS appeared to dampen
some of the response to SPS and when combined with SPS (A‐S‐A group) there was no
further increase in CRH mRNA (Figure 30). It remains to be determined why the responses
were not additive. There could be a threshold effect. Alternatively, if they both utilize a
similar downstream mechanism, then the combined response would not be additive. The
SPS‐triggered reduction of GR and FKBP5 was not observed in the group (A‐S‐A)
previously exposed to AS. In the LC, rats pre-exposed to AS did not display the SPS‐
triggered rise in CRHR1, which needs to be further investigated.
We speculate that the AS‐triggered changes in expression of NPY receptors may be
involved in dampening the responses to SPS. CRH from the PVN of the mediobasal
hypothalamus is crucial for initiating HPA response to stress. As previously observed, SPS
triggers sustained elevation of CRH gene expression 1 week following SPS

78

. Here we

show that CRH mRNA remains high 2 weeks after exposure to SPS stressors and that AS
is sufficient to trigger elevated CRH gene expression in the mediobasal hypothalamus. The
PVN receives NPY mainly from the hypothalamic arcuate nucleus, and it has been
demonstrated that numerous NPY‐containing axons innervate the PVN–CRH–containing
neurons (The Y1R, Y2R, and Y5R receptor subtypes are expressed in the mediobasal
hypothalamus, 88, 186. This pathway is essential in the regulation of neurosecretion of CRH
in response to mild stress such as AS, allowing a possible crosstalk between these two
neuropeptide systems 85, 90. Both Y1R and Y5R are postsynaptic receptors, although Y5R
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is less abundant compared with Y1R. The Y5R can be co-expressed with Y1R receptor 85,
88

. The importance of NPY and Y1R in the hypothalamus has previously been recognized

for its involvement to promote adaptive stress responses in the predator scent model of
PTSD 192-194.
Following a traumatic event, CRH from hypothalamic and extra hypothalamic
sources, especially the amygdala, changes the pattern of LC firing to one promoting
cognitive flexibility 181. By acting via CRHR1, it increases c-Fos and tyrosine hydroxylase
expression and neuronal discharge in the LC, with subsequent NE release in cortical and
subcortical structures 195, 196. CRH levels are elevated in the CSF of PTSD patients 197, 198.
In depression, a comorbid symptom in many PTSD patients, CRH levels become
chronically elevated in some patients. Sustained elevated CRH was observed in the CSF
and limbic areas of the postmortem brain of depressed patients and patients who were
victims of traumatic experience as children

199

. It has also been demonstrated that icv

infusion of CRH to rats led to pronounced, dose-dependent enhancement of the AS reflex
200

. CRH leads to the release of adrenocorticotropic hormone from the pituitary and

subsequent elevation of glucocorticoids (cortisol in humans, corticosterone in rats) in the
bloodstream. GR is activated by glucocorticoids and this facilitates the feedback inhibition
of the HPA axis. Dysregulation in GR function within brain regions that are essential for
crucial regulation and termination of the HPA axis activity might be responsible for some
of the PTSD‐related features

201, 202

. FKBP5 itself is a GR-response gene and modulates

GR function by preventing the appropriate binding and shuttling of GR to the nucleus
leading to glucocorticoid resistance

202, 203

. FKBP5 polymorphisms and promoter

methylation status have been associated with the prevalence of developing PTSD

25

. In

this part of the study, there were no changes found in mRNA levels for GR and FKPB5 in
the A‐A group of rats.
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These results may indicate that the physiological response to AS, which is
considered a mild stress, leads to rapid activation of CRH gene expression without
significant modifications of the GR–FKBP5 regulatory mechanism. However, it is
plausible that the changes in mRNAs for these genes might occur later since they are
involved in feedback regulation.
The Y1R mRNA levels were significantly increased 30 min after testing for ASR2
in the A‐A group (Figure 29) when compared with the unstressed controls. This likely
leads to the activation of NPY neurotransmission via postsynaptic Y1R receptors to PVN
to balance the increase of CRH gene expression by AS and to provide proper termination
of responses to the mild stress. Although rats from the A‐A group did not show alterations
in Y5R mRNA levels 30 min after the ASR2 test, rats exposed to AS and SPS stressors
(A‐S‐A) had Y5R mRNA levels higher than the SPS group (Figure 29). No significant
changes in Y2R mRNA levels were observed among the groups.
Expression of stress related genes associated with response of the LC to SPS was
changed by AS and SPS. CRH drives the high tonic state of the LC neuronal activity while
simultaneously decreasing phasic events in the LC 181, 182 CRH projections from the central
nucleus of the amygdala to the LC promote an anxiogenic response mediated by CRHR1.
This increased tonic LC‐NE activity is necessary and sufficient for the stress‐induced
anxiety and aversion 33. We previously showed that CRHR1 mRNA levels are increased
in some animals 1 week after exposure to SPS

96

. We found the elevation of CRHR1

mRNA levels 2 weeks after exposure to SPS (Figure 30) which is consistent with our
previous study 82, 96.
However, to our surprise, in the A‐S‐A group that had ASR1 measurement before
exposure to SPS and ASR2 measurements 2 weeks after SPS, CRHR1 mRNA levels were
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similar to the unstressed control and to the A‐A group. This would suggest that ASR could
be dampening the response to SPS stressors. This speculation can be drawn from the
elevation of Y2R and Y5R observed in response to ASR alone. However, since we do not
have measurements of gene expression at the time of administration of SPS (1 day after
basal ASR) without ASR2, it is unclear how ASR might be dampening this effect.
Elevation of glucocorticoids by exposure to ASR1 may be mediating these effects as
administration of corticosterone 12 h prior to acute stress protected against the delayed
behavioral and cellular effects of acute stress on the amygdala 204.
Y2R is a presynaptic receptor involved in regulating the release of NE. The
angiogenic role for Y2R was demonstrated when administered into some brain locations
or in transgenic animals 112, 172. Microinjections of NPY and agonist for Y2R into the LC
region had anxiolytic effects 76 and were sufficient to attenuate the postsynaptic potential
of LC neurons resulting in the inhibitory effects of NE on the cell somata and decreasing
the firing rate of the LC neurons

163

. In this study, NPY mRNA levels in the LC were

significantly reduced 2 weeks after SPS and in the A‐S‐A group. Y2R mRNA expression
was previously shown to be reduced in the LC 1 week after exposure to SPS stressors 96.
We observed a sustained reduction of Y2R mRNA 2 weeks after exposure to SPS. AS by
itself led to elevated levels of Y2R and Y5R gene expression in the LC of the A‐A group
but no changes in the Y1R gene expression was observed. Overall, SPS and AS by
themselves triggered changes in gene expression in the LC and the mediobasal
hypothalamus two weeks after exposure to stressors. Further studies are required to
understand how AS regulates the expression of specific stress‐related genes.
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Divergence in the norepinephrine transporter (NET) mRNA levels after SPS and
ASR
Our studies demonstrated a divergent NET mRNA response following either SPS
or acoustic startle response and an association between hyper arousal symptoms
originating in the LC and the divergent expression of NET mRNA in the LC in an animal
model of PTSD. Two weeks after SPS the NET mRNA expression of about 60% of the
animals were similar to the control group while approximately 40% of animals had a
higher NET mRNA expression. In a different cohort about 50% of the animals had NET
mRNAs that were similar to the control group and the other 50% of the animals had a
higher NET mRNA expression (Figure 25). This divergent NET response was also
observed after animals were exposed to acoustic startle (Figure 31). The animals that
showed increased ASR were found to have higher NET mRNA levels. In addition, there
was a negative correlation between changes in NET mRNA in the LC and ARS in the
subgroup of animal that had lower NET mRNA expression level. Furthermore, we found
that SPS has an effect on NET promoter methylation (Figure 35). The NET promoter of
the subgroup of SPS animals with lower NET mRNA expression had higher methylated
CpG sites in a proximal CpG island on the rat promoter region compared to SPS animals
with a higher NET mRNA expression.
To our knowledge, this is the first observation in a PTSD animal model that is
suggestive of a potential stress resilience or susceptible mechanism by the norepinephrine
transporter. A recent study showed differential DNA methylation levels in the NET
promoter between patients with attention deficit disorder (ADHD) and healthy controls
(HC) 59. DNA methylation is an epigenetic mechanism in which a methyl group is added
to cytosine in cytosine–phosphate–guanine sites (CpG) and has received increased
attention as a possible modulator in psychiatric disorders
125

205

. It can interfere with the

binding of transcription factors while methyl transferase activity can result to gene
repression. In postural tachycardia syndrome (POTS) patients, change in NET expression
is attributed to increased binding of the repressive MeCP2 regulatory complex, in
association with an altered histone modification composition at the promoter region of
NET

206

. Differential NET protein expression was associated with specific histone

modifications in healthy individuals and POTS. Increased levels of circulating
norepinephrine (NE) was observed in POTS patients as a result of impairment in the
clearance of NE by NET from the synapse

207

.

A mutation in the norepinephrine

transporter gene resulted in loss of function and impairment of synaptic norepinephrine
clearance leading to excessive sympathetic activation 208 as seen in the POTS patients.
Heightened arousal and reactivity, a core symptom of posttraumatic stress disorder
(PTSD) originates in the LC

154

. The association of startle response with divergent NET

mRNA expression and differential methylation in region of the NET promoter is
suggestive of a possible resilience and susceptibility mechanisms. Furthermore, we
observed a reduction in total NET protein two weeks after SPS compared to control
animals in the LC and hippocampus. A PET study showed a positive correlation between
vigilance and norepinephrine transporter availability in the LC of patients with PTSD
and in both the LC and thalamus in depressed patients

209

58

. It has also been shown that

chronic cold stress increased the proportion of plasmalemmal NET in stressed rats
compared to that in controls

210

. Chronic administration of corticosterone to rats caused

chronic stress, increasing both NET mRNA and protein levels in the rat LC as well as LC
projection regions such as the hippocampus, frontal cortex, and amygdala

156

. There is

increased central nervous system responsiveness to noradrenergic signaling in individuals
with a history of traumatic exposure

211

. The level of NET mRNA transcription can

change in response to adrenergic activation after a traumatic event.
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Exaggerated

adrenergic activation following a traumatic event can enhance memory consolidation of
the trauma resulting in an increased chance of re-experiencing the traumatic event when
a reminder presents 212.
Adrenergic α2 and Y2R receptors can also affect the concentration of NE in the
synapse. They are presynaptic receptors and control the release of NE, inhibition of
these presynaptic receptors can cause an increase in NE synaptic levels. Therefore, it is
possible that down regulation of NET could lead to an upregulation of the α 2 receptors
which negatively controls the release of NE.
Changes in the density and function of pre- and postsynaptic ARs results from
long term inhibition of NET by antidepressants such as desipramine

213

. NET also has a

higher affinity than the dopamine transporter (DAT) for dopamine (DA) and can transport
DA as well as norepinephrine (NE) 214, 215.
NET-deficient (NET-KO) mice behave like antidepressant-treated mice and
mRNAs encoding the alpha(2A)-adrenergic receptor and the alpha(2C)-adrenergic
receptor are up-regulated in the brainstem 216. NET-KO mice display higher resistance to
convulsions

50

and are supersensitive to psychostimulants 49. NET has also been a target

for the action of many drugs used to treat major depression

51

. Specific NET inhibitor

nisoxetine normalized the prepulse Inhibition deficits in dopamine transporter knockout
(DAT KO) Mice 217.
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NET Protein Expression
Reduced NET protein in hippocampus and medial prefrontal cortex after SPS
compared to control animals found in this study is in line with the finding that NET
availability in the LC and limbic brain regions from PET scans of PTSD patients was
decreased compared to healthy controls 218. These studies also found a positive correlation
between vigilance and NET availability in the LC in patients with PTSD 218. Altered NET
function was observed in patients with major depression, with elevated NET availability
in the thalamic subregion connected to the prefrontal cortex. This was positively correlated
with attention 209. Reduced NET expression in LC is likely to be associated with increased
LC neuronal activity, this remains to be determined. However, NET activity can be
regulated not only by its total protein levels, but also by its plasmalemmal distribution.
Chronic cold stress increased the proportion of NET on the plasma membrane in the rat
prefrontal cortex 210.
The discrepancy between the changes in mRNA and protein might reflect a lag
between transcription and translation or transport of the protein. Also SPS might be
altering the turnover rate of the protein. Further studies with more projection areas and a
more detailed time course could help to clarify this.
NET is also regulated by glycosylation. Carbohydrate units of glycoproteins are
involved in controlling protein folding, stabilizing protein conformation, protecting
against proteolysis, and regulating intracellular and surface trafficking

219

. Poorly or

unglycosylated forms of NET are not directed to the surface and are retained in the
cytoplasm 220, 221. In addition, PKC activation induces phosphorylation of both serine and
threonine residues in rat and human NETs, resulting in transporter phosphorylation and
down-regulation 222.
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We demonstrate for the first time a divergent NET mRNA response to stress that
can serve as a molecular basis for an in-depth study on the involvement of NET and the
LC-NE system in predicting resilience or susceptibility in PTSD. These findings will
facilitate in the identifications of biomarkers that will help in diagnosis and more effective
treatments of PTSD symptoms in patients.
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Limitations

Some limitations of the NET study would be addressed in future studies by
increasing the sample size to further study the relationship between hyperarousal
symptoms and time course in NET expression. In addition, to evaluate NET protein
expression in the medial prefrontal cortex, amygdala, LC and hippocampus.
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Possible future experiments to evaluate if NET is necessary and sufficient to attenuate
hyperarousal response.

Possible future experiments to further decipher the role of NET in ASR would
include pharmacological experiments inhibiting NET with reboxetine or other selective
NET inhibition and then expose animals to SPS or acoustic startle to evaluate if down
regulation of NET just before ASR will affect the ASR. However, because down regulation
of NET could lead to an upregulation of the α2 receptors which negatively controls the
release of NE, upregulation of mRNAs encoding the alpha(2A)-adrenergic receptor and
the alpha(2C)-adrenergic receptor in the brainstem and upregulation of dopamine
transporters. The precise conditional control of NET expression in vivo could be more
suitable to evaluate the effect of NET on ASR. For example, the Cre/lox site-specific
recombination system can allow the control of a specific gene activity in space and time
in almost any tissue of the animal. To make the Cre/lox system inducible, liganddependent chimeric Cre recombinases, CreER recombinases, have been developed
224

223,

. They consist of Cre fused to mutated hormone-binding domains of the estrogen

receptor. The CreER recombinases are inactive, but can be activated by the synthetic
estrogen receptor ligand 4-hydroxytamoxifen (OHT), therefore allowing for external
temporal control of Cre activity. A schematic of potential animal construct is shown
below.
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To make it more LC specific, cocktail of lenti-virus construct of CreER fused to
the human synapsin promoter and a floxed NET promoter construct will be injected into
the LC. This will knock down the expression of NET more precisely and specifically in
the LC. Administration of tamoxifen will allow for conditional downregulation of NET
before and after SPS or ASR. We would expect that this would lead to reduced ASR.
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